<Summary id="CDR0000062881" LegacyPDQID=""><SummaryMetaData><SummaryType>Treatment</SummaryType><SummaryAudience>Health professionals</SummaryAudience><SummaryLanguage>English</SummaryLanguage><SummaryDescription>Mycosis fungoides and other cutaneous T-cell lymphomas are neoplasias of malignant T lymphocytes that affect the skin. Learn about the clinical presentation, prognosis, staging, and treatment for mycosis fungoides and other cutaneous T-cell lymphomas in this expert-reviewed summary.</SummaryDescription><SummaryURL xref="https://www.cancer.gov/types/lymphoma/hp/mycosis-fungoides-treatment-pdq">Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas (PDQ®): Treatment</SummaryURL><SummaryToggleURL xref="https://www.cancer.gov/types/lymphoma/patient/mycosis-fungoides-treatment-pdq">Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas (PDQ®): Treatment</SummaryToggleURL><SummaryEditorialBoard ref="CDR0000028327">PDQ Adult Treatment Editorial Board</SummaryEditorialBoard><MainTopics><TermRef ref="CDR0000038223">mycosis fungoides/Sezary syndrome</TermRef></MainTopics><SummaryAbstract><Para id="_297">This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of mycosis fungoides and other cutaneous T-cell lymphomas. It is intended as a resource to inform and assist clinicians in the care of their patients. It does not provide formal guidelines or recommendations for making health care decisions.</Para><Para id="_298">This summary is reviewed regularly and updated as necessary by the PDQ Adult Treatment Editorial Board, which is editorially independent of the National Cancer Institute (NCI). The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).</Para></SummaryAbstract><SummaryKeyWords><SummaryKeyWord>mycosis fungoides and other cutaneous T-cell lymphomas</SummaryKeyWord></SummaryKeyWords></SummaryMetaData><SummaryTitle>Mycosis Fungoides  and Other Cutaneous T-Cell Lymphomas Treatment (PDQ®)–Health Professional Version</SummaryTitle><AltTitle TitleType="Browser">Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas Treatment (PDQ®)</AltTitle><AltTitle TitleType="CancerTypeHomePage">Mycosis Fungoides and Other Adult Cutaneous T-Cell Lymphomas Treatment</AltTitle><SummarySection id="_1"><SectMetaData><SpecificDiagnosis ref="CDR0000038223">mycosis fungoides/Sezary syndrome</SpecificDiagnosis><SpecificDiagnosis ref="CDR0000043725">cutaneous T-cell non-Hodgkin lymphoma</SpecificDiagnosis><SectionType>Prognosis--legacy</SectionType></SectMetaData><Title>General Information About Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas </Title><SummarySection id="_287"><Title>Clinical Presentation</Title><Para id="_3">Cutaneous T-cell lymphomas, which include mycosis fungoides  and Sézary syndrome,  are neoplasias of malignant
T lymphocytes that usually possess the helper/inducer cell surface phenotype and initially present as skin involvement.<Reference refidx="1"/>   Cutaneous T-cell lymphomas should be distinguished from other T-cell lymphomas that
involve the skin, such as anaplastic large cell lymphoma (CD30 positive),
peripheral T-cell lymphoma (CD30 negative, with no epidermal involvement),
or adult T-cell leukemia/lymphoma (usually with systemic involvement).<Reference refidx="2"/><Reference refidx="3"/>  For more information about these types of T-cell lymphomas, see <SummaryRef href="CDR0000811763" url="/types/lymphoma/hp/peripheral-t-cell-lymphoma-pdq">Peripheral T-Cell Non-Hodgkin Lymphoma Treatment</SummaryRef>.  
</Para><Para id="_369">Typically, the natural history of cutaneous T-cell lymphoma is indolent.<Reference refidx="4"/>  Symptoms of the disease
may be present for long periods, in a range  of 2 to 10 years, because cutaneous eruptions wax and wane
before being confirmed by biopsy.  Cutaneous T-cell lymphomas are  treatable with
available topical therapy, systemic therapy, or both.  Curative modalities  have
proven elusive, with the possible exception of patients with minimal
disease confined to the skin.
</Para><Para id="_370">In
addition, several benign or indolent conditions can be confused with
mycosis fungoides.  It is important to consult with a pathologist who has
expertise in distinguishing these conditions.<Reference refidx="1"/>
</Para></SummarySection><SummarySection id="_286"><Title>Prognosis and Survival</Title><Para id="_563">The prognosis of patients with cutaneous T-cell lymphomas is based on the extent of disease (stage) at
presentation.<Reference refidx="5"/> The presence of lymphadenopathy and involvement of
peripheral blood and viscera increase in likelihood with worsening cutaneous
involvement and define poor prognostic groups.<Reference refidx="5"/><Reference refidx="6"/><Reference refidx="7"/><Reference refidx="8"/> The Cutaneous Lymphoma International Consortium retrospectively reviewed 1,275 patients and found that the following four independent prognostic markers indicate a worse survival:<Reference refidx="9"/></Para><ItemizedList id="_545" Style="bullet">
     <ListItem>Stage IV disease.</ListItem><ListItem>Age older than 60 years.</ListItem><ListItem>Large cell transformation.</ListItem><ListItem>Elevated lactate dehydrogenase.</ListItem></ItemizedList><Para id="_4">  The median survival
following diagnosis varies according to stage.  Patients with stage IA disease
have a median survival of 20 years or more.  Most deaths for this
group are not caused by, nor are they related to, mycosis fungoides.<Reference refidx="10"/><Reference refidx="11"/>  In contrast, more
than 50% of patients with stage III through stage IV disease die of mycosis fungoides, with a
median survival of approximately 5 years.<Reference refidx="7"/><Reference refidx="9"/><Reference refidx="12"/><Reference refidx="13"/> The Cutaneous Lymphoma International Prognostic index used male sex, age older than 60 years, plaques, lymph nodes, blood involvement, and visceral involvement as poor prognostic factors to define predicted overall survival (OS) and progression-free survival in both early-stage and advanced-stage groups.<Reference refidx="14"/> 
</Para><Para id="_372">A report on 1,798 patients from the <ExternalRef xref="https://seer.cancer.gov/">National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) Program</ExternalRef> database found an increase in second malignancies in patients with mycosis fungoides (standardized incidence ratio, 1.32; 95% confidence interval [CI], 1.15–1.52), especially for Hodgkin lymphoma, non-Hodgkin lymphoma, and myeloma.<Reference refidx="15"/> Another report on 4,459 patients from the SEER database found that the 19.2% of African American patients with mycosis fungoides had shorter OS, potentially attributable to disease characteristics, socioeconomic status, and type of therapy (hazard ratio, 1.47; 95% CI, 1.25–1.74; <Emphasis>P</Emphasis> &lt; .001).<Reference refidx="16"/></Para><Para id="_6">Cutaneous disease can manifest as an eczematous patch or plaque stage
covering less than 10% of the body surface (T1), a plaque stage covering
10%  or more of the body surface (T2), or as tumors
(T3) that frequently undergo necrotic ulceration.<Reference refidx="17"/><Reference refidx="18"/>  Several retrospective studies showed that 20% of patients have disease that progresses from stage I or II to stage III or IV.<Reference refidx="19"/><Reference refidx="20"/><Reference refidx="21"/> Sézary syndrome presents with generalized erythroderma (T4) and peripheral blood involvement.  However, there is some disagreement about  whether mycosis fungoides and Sézary syndrome are actually variants of the same disease.<Reference refidx="22"/> The same retrospective study with a median follow-up of 14.5 years found that only 3% of 1,422 patients progressed from mycosis fungoides to Sézary syndrome.<Reference refidx="19"/> 
</Para><Para id="_373"> There is consensus that patients with Sézary syndrome (leukemic involvement) have a poor prognosis (median survival, 4 years), with or without the typical generalized erythroderma.<Reference refidx="23"/><Reference refidx="24"/> Cytologic transformation from a low-grade lymphoma to a high-grade
lymphoma (large cell transformation) occurs rarely (&lt;5%) during the course of these diseases and is associated
with a poor prognosis.<Reference refidx="25"/><Reference refidx="26"/><Reference refidx="27"/>  A retrospective analysis of 100 cases with large cell transformation found reduced disease-specific survival with extracutaneous transformation, increased extent of skin lesions, and CD30 negativity.<Reference refidx="28"/> A common cause of death during the tumor phase is
septicemia caused by  chronic skin
infection with staph species, herpes simplex, herpes zoster, and fungal skin infections.<Reference refidx="29"/><Reference refidx="30"/></Para><Para id="_568">Folliculotropic mycosis fungoides  is a variant of mycosis fungoides marked by folliculotropic, rather than epidermotropic, neoplastic infiltrates, with preferential location in the head and neck area.<Reference refidx="31"/> Early plaque-stage folliculotropic mycosis fungoides have a very indolent prognosis, while extracutaneous disease portends a very poor prognosis.<Reference refidx="31"/></Para></SummarySection><ReferenceSection><Citation idx="1" PMID="28872191">Wilcox RA: Cutaneous T-cell lymphoma: 2017 update on diagnosis, risk-stratification, and management. Am J Hematol 92 (10): 1085-1102, 2017.</Citation><Citation idx="2" PMID="9207472" MedlineID="97351096">Willemze R, Kerl H, Sterry W, et al.: EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood 90 (1): 354-71, 1997.</Citation><Citation idx="3" PMID="8068936" MedlineID="94348057">Harris NL, Jaffe ES, Stein H, et al.: A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 84 (5): 1361-92, 1994.</Citation><Citation idx="4" PMID="8839829" MedlineID="96437013">Diamandidou E, Cohen PR, Kurzrock R: Mycosis fungoides and Sezary syndrome. Blood 88 (7): 2385-409, 1996.</Citation><Citation idx="5" PMID="20855822">Agar NS, Wedgeworth E, Crichton S, et al.: Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol 28 (31): 4730-9, 2010.</Citation><Citation idx="6" PMID="22850569">Talpur R, Singh L, Daulat S, et al.: Long-term outcomes of 1,263 patients with mycosis fungoides and Sézary syndrome from 1982 to 2009. Clin Cancer Res 18 (18): 5051-60, 2012.</Citation><Citation idx="7" PMID="12873880">Kim YH, Liu HL, Mraz-Gernhard S, et al.: Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression. Arch Dermatol 139 (7): 857-66, 2003.</Citation><Citation idx="8" PMID="25817937">Alberti-Violetti S, Talpur R, Schlichte M, et al.: Advanced-stage mycosis fungoides and Sézary syndrome: survival and response to treatment. Clin Lymphoma Myeloma Leuk 15 (6): e105-12, 2015.</Citation><Citation idx="9" PMID="26438120">Scarisbrick JJ, Prince HM, Vermeer MH, et al.: Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model. J Clin Oncol 33 (32): 3766-73, 2015.</Citation><Citation idx="10" PMID="8915308" MedlineID="97072542">Kim YH, Jensen RA, Watanabe GL, et al.: Clinical stage IA (limited patch and plaque) mycosis fungoides. A long-term outcome analysis. Arch Dermatol 132 (11): 1309-13, 1996.</Citation><Citation idx="11" PMID="24713743">Vollmer RT: A review of survival in mycosis fungoides. Am J Clin Pathol 141 (5): 706-11, 2014.</Citation><Citation idx="12" PMID="10071312" MedlineID="99168870">Zackheim HS, Amin S, Kashani-Sabet M, et al.: Prognosis in cutaneous T-cell lymphoma by skin stage: long-term survival in 489 patients. J Am Acad Dermatol 40 (3): 418-25, 1999.</Citation><Citation idx="13" PMID="11157031" MedlineID="21104129">de Coninck EC, Kim YH, Varghese A, et al.: Clinical characteristics and outcome of patients with extracutaneous mycosis fungoides. J Clin Oncol 19 (3): 779-84, 2001.</Citation><Citation idx="14" PMID="23735705">Benton EC, Crichton S, Talpur R, et al.: A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome. Eur J Cancer 49 (13): 2859-68, 2013.</Citation><Citation idx="15" PMID="17224541">Huang KP, Weinstock MA, Clarke CA, et al.: Second lymphomas and other malignant neoplasms in patients with mycosis fungoides and Sezary syndrome: evidence from population-based and clinical cohorts. Arch Dermatol 143 (1): 45-50, 2007.</Citation><Citation idx="16" PMID="28645647">Su C, Nguyen KA, Bai HX, et al.: Racial disparity in mycosis fungoides: An analysis of 4495 cases from the US National Cancer Database. J Am Acad Dermatol 77 (3): 497-502.e2, 2017.</Citation><Citation idx="17" PMID="10920140" MedlineID="20381203">Siegel RS, Pandolfino T, Guitart J, et al.: Primary cutaneous T-cell lymphoma: review and current concepts. J Clin Oncol 18 (15): 2908-25, 2000.</Citation><Citation idx="18" PMID="8622396" MedlineID="96177218">Lorincz AL: Cutaneous T-cell lymphoma (mycosis fungoides) Lancet 347 (9005): 871-6, 1996.</Citation><Citation idx="19" PMID="22674564">Quaglino P, Pimpinelli N, Berti E, et al.: Time course, clinical pathways, and long-term hazards risk trends of disease progression in patients with classic mycosis fungoides: a multicenter, retrospective follow-up study from the Italian Group of Cutaneous Lymphomas. Cancer 118 (23): 5830-9, 2012.</Citation><Citation idx="20" PMID="26053896">Wernham AG, Shah F, Amel-Kashipaz R, et al.: Stage I mycosis fungoides: frequent association with a favourable prognosis but disease progression and disease-specific mortality may occur. Br J Dermatol 173 (5): 1295-7, 2015.</Citation><Citation idx="21" PMID="25458019">Desai M, Liu S, Parker S: Clinical characteristics, prognostic factors, and survival of 393 patients with mycosis fungoides and Sézary syndrome in the southeastern United States: a single-institution cohort. J Am Acad Dermatol 72 (2): 276-85, 2015.</Citation><Citation idx="22" PMID="21145619">Olsen EA, Rook AH, Zic J, et al.: Sézary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). J Am Acad Dermatol 64 (2): 352-404, 2011.</Citation><Citation idx="23" PMID="22640839">Kubica AW, Davis MD, Weaver AL, et al.: Sézary syndrome: a study of 176 patients at Mayo Clinic. J Am Acad Dermatol 67 (6): 1189-99, 2012.</Citation><Citation idx="24" PMID="28012574">Thompson AK, Killian JM, Weaver AL, et al.: Sézary syndrome without erythroderma: A review of 16 cases at Mayo Clinic. J Am Acad Dermatol 76 (4): 683-688, 2017.</Citation><Citation idx="25" PMID="7661601" MedlineID="95390698">Kim YH, Bishop K, Varghese A, et al.: Prognostic factors in erythrodermic mycosis fungoides and the Sézary syndrome. Arch Dermatol 131 (9): 1003-8, 1995.</Citation><Citation idx="26" PMID="18647960">Arulogun SO, Prince HM, Ng J, et al.: Long-term outcomes of patients with advanced-stage cutaneous T-cell lymphoma and large cell transformation. Blood 112 (8): 3082-7, 2008.</Citation><Citation idx="27" PMID="24438952">Kadin ME, Hughey LC, Wood GS: Large-cell transformation of mycosis fungoides-differential diagnosis with implications for clinical management: a consensus statement of the US Cutaneous Lymphoma Consortium. J Am Acad Dermatol 70 (2): 374-6, 2014.</Citation><Citation idx="28" PMID="22160616">Benner MF, Jansen PM, Vermeer MH, et al.: Prognostic factors in transformed mycosis fungoides: a retrospective analysis of 100 cases. Blood 119 (7): 1643-9, 2012.</Citation><Citation idx="29" PMID="18489588">Talpur R, Bassett R, Duvic M: Prevalence and treatment of Staphylococcus aureus colonization in patients with mycosis fungoides and Sézary syndrome. Br J Dermatol 159 (1): 105-12, 2008.</Citation><Citation idx="30" PMID="28249285">Lebas E, Arrese JE, Nikkels AF: Risk Factors for Skin Infections in Mycosis Fungoides. Dermatology 232 (6): 731-737, 2016.</Citation><Citation idx="31" PMID="27276223">van Santen S, Roach RE, van Doorn R, et al.: Clinical Staging and Prognostic Factors in Folliculotropic Mycosis Fungoides. JAMA Dermatol 152 (9): 992-1000, 2016.</Citation></ReferenceSection></SummarySection><SummarySection id="_7"><SectMetaData><SpecificDiagnosis ref="CDR0000038223">mycosis fungoides/Sezary syndrome</SpecificDiagnosis><SpecificDiagnosis ref="CDR0000043725">cutaneous T-cell non-Hodgkin lymphoma</SpecificDiagnosis><SectionType>Cellular classification--legacy</SectionType></SectMetaData><Title>Cellular Classification of Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas  </Title><Para id="_8">The histological diagnosis of mycosis fungoides  and other cutaneous T-cell lymphomas 
is usually difficult to determine in the initial stages of the disease and may require the
review of multiple biopsies by an experienced pathologist.
</Para><Para id="_9">A definitive diagnosis from a skin biopsy requires the presence of cutaneous T-cell lymphoma cells
(convoluted lymphocytes), a band-like upper dermal infiltrate, and epidermal
infiltrations with Pautrier abscesses (collections of neoplastic
lymphocytes).  A definitive diagnosis of Sézary syndrome may be made from a peripheral blood
evaluation when skin biopsies are consistent with the diagnosis. Supportive evidence for circulating Sézary cells is provided by T-cell receptor gene analysis, identification of the atypical lymphocytes with hyperconvoluted or cerebriform nuclei, and flow cytometry with the characteristic deletion of cell surface markers such as CD7 and CD26.   However, none of these is individually pathognomonic for lymphoma.<Reference refidx="1"/><Reference refidx="2"/></Para><Para id="_736">Established criteria for defining Sézary syndrome generally require identification of (1) a circulating T-cell clone by rearrangement of the T-cell receptor, plus (2) a level of Sézary cells in the blood of at least 1,000/μL.<Reference refidx="3"/><Reference refidx="4"/> It is less clear if other findings (such as a CD4:CD8 ratio ≥10, or the use of percentages instead of absolute numbers of atypical lymphocytes by flow cytometry) are reliable staging data in the absence of blood Sézary cell levels of at least 1,000/μL.<Reference refidx="5"/></Para><ReferenceSection><Citation idx="1" PMID="21145619">Olsen EA, Rook AH, Zic J, et al.: Sézary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). J Am Acad Dermatol 64 (2): 352-404, 2011.</Citation><Citation idx="2" PMID="11745245" MedlineID="21610187">Fraser-Andrews EA, Russell-Jones R, Woolford AJ, et al.: Diagnostic and prognostic importance of T-cell receptor gene analysis in patients with Sézary syndrome. Cancer 92 (7): 1745-52, 2001.</Citation><Citation idx="3" PMID="17540844">Olsen E, Vonderheid E, Pimpinelli N, et al.: Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 110 (6): 1713-22, 2007.</Citation><Citation idx="4" PMID="34758074">Olsen EA, Whittaker S, Willemze R, et al.: Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC. Blood 140 (5): 419-437, 2022.</Citation><Citation idx="5" PMID="38848513">Chrisman LP, Trimark PF, Pang Y, et al.: Updated cutaneous T-cell lymphoma TNMB staging criteria fail to identify patients with Sézary syndrome with low blood burden. Blood 144 (8): 914-917, 2024.</Citation></ReferenceSection></SummarySection><SummarySection id="_10"><SectMetaData><SpecificDiagnosis ref="CDR0000038223">mycosis fungoides/Sezary syndrome</SpecificDiagnosis><SpecificDiagnosis ref="CDR0000043725">cutaneous T-cell non-Hodgkin lymphoma</SpecificDiagnosis><SectionType>Stage explanation--legacy</SectionType></SectMetaData><Title>Stage Information for Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas </Title><Para id="_11">The American Joint Committee on Cancer (AJCC) has designated staging by TNM (tumor, node, metastasis) classification to define cutaneous T-cell lymphomas.<Reference refidx="1"/>  Peripheral blood
involvement with cutaneous T-cell lymphoma  cells is correlated with more
advanced skin stage, lymph node and visceral involvement, and shortened
survival. </Para><Para id="_214">Cutaneous T-cell lymphomas also have a formal staging system proposed by the International Society for Cutaneous Lymphomas and the European Organisation for Research and Treatment of Cancer.<Reference refidx="2"/><Reference refidx="3"/></Para><Table id="_584"><Title>Table 1.  Histopathological Staging of Lymph Nodes in Cutaneous T-Cell Lymphoma<Superscript>a</Superscript></Title><TGroup Cols="3"><ColSpec ColName="col1" ColNum="1" ColWidth="33.33%"/><ColSpec ColName="col2" ColNum="2" ColWidth="33.33%"/><ColSpec ColName="col3" ColNum="3" ColWidth="33.33%"/><THead><Row><entry Align="Center">EORTC Classification</entry><entry Align="Center">Dutch System</entry><entry Align="Center">NCI-VA  Classification</entry></Row></THead><TFoot><Row><entry NameEnd="col3" NameSt="col1">DL = dermatopathic lymphadenopathy; EORTC = European Organisation for Research and Treatment of Cancer; LN = lymph nodes; N = regional lymph node; NCI = National Cancer Institute; VA = U.S. Department of Veterans Affairs.</entry></Row><Row><entry NameEnd="col3" NameSt="col1"><Superscript>a</Superscript>Reprinted with permission from AJCC: Primary Cutaneous Lymphomas. In: Amin MB, Edge SB, Greene FL, et al., eds.: AJCC Cancer Staging Manual. 8th ed. New York, NY: Springer, 2017, pp. 967–72.</entry></Row></TFoot><TBody><Row><entry MoreRows="2">N1</entry><entry MoreRows="2">Grade 1: DL</entry><entry>LN0: No atypical lymphocytes.</entry></Row><Row><entry>LN1: Occasional and isolated atypical lymphocytes (not arranged in clusters).</entry></Row><Row><entry>LN2: Many atypical lymphocytes or lymphocytes in 3-6‒cell clusters.</entry></Row><Row><entry>N2</entry><entry>Grade 2: DL; early involvement by mycosis fungoides (presence of cerebriform nuclei &lt;7.5 µm [micrometer]).</entry><entry>LN3: Aggregates of atypical lymphocytes; nodal architecture preserved.</entry></Row><Row><entry MoreRows="1">N3</entry><entry>Grade 3: Partial effacement of lymph node architecture; many atypical cerebriform mononuclear cells.</entry><entry MoreRows="1">LN4: Partial/complete effacement of nodal architecture by atypical lymphocytes or frankly neoplastic cells.</entry></Row><Row><entry>Grade 4: Complete effacement.</entry></Row></TBody></TGroup></Table><Table id="_580"><Title>Table 2.  Definitions of TNM Stages IA and IB<Superscript>a</Superscript></Title><TGroup Cols="5"><ColSpec ColName="col1" ColNum="1" ColWidth="20.00%"/><ColSpec ColName="col2" ColNum="2" ColWidth="20.00%"/><ColSpec ColName="col3" ColNum="3" ColWidth="20.00%"/><ColSpec ColName="col4" ColNum="4" ColWidth="20.00%"/><ColSpec ColName="col5" ColNum="5" ColWidth="20.00%"/><THead><Row><entry Align="Center">Stage	</entry><entry Align="Center">TNM	</entry><entry Align="Center">Description	</entry><entry Align="Center">B	</entry><entry Align="Center">Peripheral Blood Involvement  Criteria</entry></Row></THead><TFoot><Row><entry NameEnd="col5" NameSt="col1">T = primary tumor; N = regional lymph node; M = distant metastasis; B = peripheral blood involvement.</entry></Row><Row><entry NameEnd="col5" NameSt="col1"><Superscript>a</Superscript>Reprinted with permission from AJCC: Primary Cutaneous Lymphomas. In: Amin MB, Edge SB, Greene FL, et al., eds.: AJCC Cancer Staging Manual. 8th ed. New York, NY: Springer, 2017, pp. 967–72.</entry></Row><Row><entry NameEnd="col5" NameSt="col1">The explanations for superscripts b through f are at the end of <SummaryRef href="CDR0000062881#_583" url="/types/lymphoma/hp/mycosis-fungoides-treatment-pdq">Table 5</SummaryRef>.</entry></Row></TFoot><TBody><Row><entry MoreRows="6">IA </entry><entry MoreRows="6">T1, N0, M0 </entry><entry>T1 = Limited patches,<Superscript>b</Superscript> papules, and/or plaques<Superscript>c</Superscript> covering &lt;10% of the skin surface. </entry><entry MoreRows="6">B0,1</entry><entry MoreRows="1">B0 = Absence of significant blood involvement: ≤5% of peripheral blood lymphocytes are atypical (Sézary) cells.<Superscript>d</Superscript></entry></Row><Row><entry>–T1a = T1a (patch only).</entry></Row><Row><entry MoreRows="1">–T1b = T1b (plaque ± patch).</entry><entry>–B0a = Clone negative<Superscript>e</Superscript></entry></Row><Row><entry>–B0b = Clone positive<Superscript>e</Superscript></entry></Row><Row><entry>N0 = No clinically abnormal peripheral lymph nodes;<Superscript>f</Superscript> biopsy not required.</entry><entry>B1 = Low blood tumor burden: &gt;5% of peripheral blood lymphocytes are atypical (Sézary) cells, but does not meet the criteria of B2.</entry></Row><Row><entry MoreRows="1">M0 = No visceral organ involvement.</entry><entry>–B1a = Clone negative<Superscript>e</Superscript></entry></Row><Row><entry>–B1b = Clone positive<Superscript>e</Superscript></entry></Row><Row><entry MoreRows="4">IB</entry><entry MoreRows="4">T2, N0, M0</entry><entry>T2 = Patches, papules, or plaques covering ≥10% of the skin surface.</entry><entry MoreRows="4">B0,1</entry><entry MoreRows="4">See B0, B1 descriptions above in this table, Stage IA.</entry></Row><Row><entry>–T2a = T2a (patch only).</entry></Row><Row><entry>–T2b = T2b (plaque ± patch).</entry></Row><Row><entry>N0 = No clinically abnormal peripheral lymph nodes;<Superscript>f</Superscript> biopsy not required.</entry></Row><Row><entry>M0 = No visceral organ involvement.</entry></Row></TBody></TGroup></Table><Table id="_581"><Title>Table 3.  Definitions of TNM Stages IIA and IIB<Superscript>a</Superscript></Title><TGroup Cols="5"><ColSpec ColName="col1" ColNum="1" ColWidth="19.73%"/><ColSpec ColName="col2" ColNum="2" ColWidth="19.73%"/><ColSpec ColName="col3" ColNum="3" ColWidth="29.75%"/><ColSpec ColName="col4" ColNum="4" ColWidth="14.51%"/><ColSpec ColName="col5" ColNum="5" ColWidth="16.25%"/><THead><Row><entry Align="Center">Stage	</entry><entry Align="Center">TNM	</entry><entry Align="Center">Description	</entry><entry Align="Center">B	</entry><entry Align="Center">Peripheral Blood Involvement Criteria</entry></Row></THead><TFoot><Row><entry NameEnd="col5" NameSt="col1">T = primary tumor; N = regional lymph node; M = distant metastasis; B = peripheral blood involvement; LN = lymph nodes; NCI = National Cancer Institute.</entry></Row><Row><entry NameEnd="col5" NameSt="col1"><Superscript>a</Superscript>Reprinted with permission from AJCC: Primary Cutaneous Lymphomas. In: Amin MB, Edge SB, Greene FL, et al., eds.: AJCC Cancer Staging Manual. 8th ed. New York, NY: Springer, 2017, pp. 967–72.</entry></Row><Row><entry NameEnd="col5" NameSt="col1">The explanations for superscripts e through g are at the end of <SummaryRef href="CDR0000062881#_583" url="/types/lymphoma/hp/mycosis-fungoides-treatment-pdq">Table 5</SummaryRef>.</entry></Row></TFoot><TBody><Row><entry MoreRows="7">IIA</entry><entry MoreRows="7">T1,2; N1,2; M0</entry><entry>See T1–2 descriptions above in <SummaryRef href="CDR0000062881#_580" url="/types/lymphoma/hp/mycosis-fungoides-treatment-pdq">Table 2</SummaryRef>, Stages IA, IB.</entry><entry MoreRows="7">B0,1</entry><entry MoreRows="7">See B0, B1 descriptions above in <SummaryRef href="CDR0000062881#_580" url="/types/lymphoma/hp/mycosis-fungoides-treatment-pdq">Table 2</SummaryRef>, Stage IA.</entry></Row><Row><entry>N1 = Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 1 or NCI LN0–2.</entry></Row><Row><entry>–N1a = Clone negative.<Superscript>e</Superscript></entry></Row><Row><entry>–N1b = Clone positive.<Superscript>e</Superscript></entry></Row><Row><entry>N2 = Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 2 or NCI LN3.</entry></Row><Row><entry>–N2a = Clone negative.<Superscript>e</Superscript></entry></Row><Row><entry>–N2b = Clone positive.<Superscript>e</Superscript></entry></Row><Row><entry>M0 = No visceral organ involvement.</entry></Row><Row><entry MoreRows="5">IIB</entry><entry MoreRows="5">T3, N0–2, M0</entry><entry>T3 = One or more tumors<Superscript>g</Superscript> (≥1 cm in diameter).</entry><entry MoreRows="5">B0,1</entry><entry MoreRows="5">See B0, B1 descriptions above in <SummaryRef href="CDR0000062881#_580" url="/types/lymphoma/hp/mycosis-fungoides-treatment-pdq">Table 2</SummaryRef>, Stage IA.</entry></Row><Row><entry>–T3a = Multiple lesions involving 2 noncontiguous body regions.</entry></Row><Row><entry>–T3b = Multiple lesions involving ≥3 body regions.</entry></Row><Row><entry>N0 = No clinically abnormal peripheral lymph nodes;<Superscript>f</Superscript> biopsy not required.</entry></Row><Row><entry>See N1–2 descriptions above in this table, Stage IIA</entry></Row><Row><entry>M0 = No visceral organ involvement.</entry></Row></TBody></TGroup></Table><Table id="_582"><Title>Table 4.  Definitions of TNM Stages III, IIIA, and IIIB<Superscript>a</Superscript></Title><TGroup Cols="5"><ColSpec ColName="col1" ColNum="1" ColWidth="19.80%"/><ColSpec ColName="col2" ColNum="2" ColWidth="19.80%"/><ColSpec ColName="col3" ColNum="3" ColWidth="24.12%"/><ColSpec ColName="col4" ColNum="4" ColWidth="15.97%"/><ColSpec ColName="col5" ColNum="5" ColWidth="20.28%"/><THead><Row><entry Align="Center">Stage	</entry><entry Align="Center">TNM	</entry><entry Align="Center">Description	</entry><entry Align="Center">B	</entry><entry Align="Center">Peripheral Blood Involvement Criteria</entry></Row></THead><TFoot><Row><entry NameEnd="col5" NameSt="col1">T = primary tumor; N = regional lymph node; M = distant metastasis; B = peripheral blood involvement.</entry></Row><Row><entry NameEnd="col5" NameSt="col1"><Superscript>a</Superscript>Reprinted with permission from AJCC: Primary Cutaneous Lymphomas. In: Amin MB, Edge SB, Greene FL, et al., eds.: AJCC Cancer Staging Manual. 8th ed. New York, NY: Springer, 2017, pp. 967–72.</entry></Row></TFoot><TBody><Row><entry MoreRows="2">III</entry><entry MoreRows="2">T4, N0–2, M0</entry><entry>T4 = Confluence of erythema covering ≥80% of body surface area.</entry><entry MoreRows="2">B0,1</entry><entry MoreRows="2">See B0, B1 descriptions above in <SummaryRef href="CDR0000062881#_580" url="/types/lymphoma/hp/mycosis-fungoides-treatment-pdq">Table 2</SummaryRef>, Stage IA.</entry></Row><Row><entry>See N0–2 descriptions above in <SummaryRef href="CDR0000062881#_581" url="/types/lymphoma/hp/mycosis-fungoides-treatment-pdq">Table 3</SummaryRef>, Stages IIA,  IIB.</entry></Row><Row><entry>M0 = No visceral organ involvement.</entry></Row><Row><entry MoreRows="2">IIIA</entry><entry MoreRows="2">T4, N0–2, M0</entry><entry>T4 = Confluence of erythema covering ≥80% of body surface area.</entry><entry MoreRows="2">B0</entry><entry MoreRows="2">See B0 description above in <SummaryRef href="CDR0000062881#_580" url="/types/lymphoma/hp/mycosis-fungoides-treatment-pdq">Table 2</SummaryRef>, Stage IA.</entry></Row><Row><entry>See N0–2 descriptions above in <SummaryRef href="CDR0000062881#_581" url="/types/lymphoma/hp/mycosis-fungoides-treatment-pdq">Table 3</SummaryRef>, Stages IIA,  IIB.</entry></Row><Row><entry>M0 = No visceral organ involvement.</entry></Row><Row><entry MoreRows="2">IIIB</entry><entry MoreRows="2">T4, N0–2, M0</entry><entry>T4 = Confluence of erythema covering ≥80% of body surface area.</entry><entry MoreRows="2">B1</entry><entry MoreRows="2">See B1 description above in <SummaryRef href="CDR0000062881#_580" url="/types/lymphoma/hp/mycosis-fungoides-treatment-pdq">Table 2</SummaryRef>, Stage IA.</entry></Row><Row><entry>See N0–2 descriptions above in <SummaryRef href="CDR0000062881#_581" url="/types/lymphoma/hp/mycosis-fungoides-treatment-pdq">Table 3</SummaryRef>, Stages IIA, IIB.</entry></Row><Row><entry>M0 = No visceral organ involvement.</entry></Row></TBody></TGroup></Table><Table id="_583"><Title>Table 5.  Definitions of TNM Stages IVA1, IVA2,  and IVB<Superscript>a</Superscript></Title><TGroup Cols="5"><ColSpec ColName="col1" ColNum="1" ColWidth="16.31%"/><ColSpec ColName="col2" ColNum="2" ColWidth="16.31%"/><ColSpec ColName="col3" ColNum="3" ColWidth="27.56%"/><ColSpec ColName="col4" ColNum="4" ColWidth="19.24%"/><ColSpec ColName="col5" ColNum="5" ColWidth="20.55%"/><THead><Row><entry Align="Center">Stage	</entry><entry Align="Center">TNM	</entry><entry Align="Center">Description	</entry><entry Align="Center">B	</entry><entry Align="Center">Peripheral Blood Involvement Criteria</entry></Row></THead><TFoot><Row><entry NameEnd="col5" NameSt="col1">T = primary tumor; N = regional lymph node; M = distant metastasis; B = peripheral blood involvement; LN = lymph nodes; NCI = National Cancer Institute.</entry></Row><Row><entry NameEnd="col5" NameSt="col1"><Superscript>a</Superscript>Reprinted with permission from AJCC: Primary Cutaneous Lymphomas. In: Amin MB, Edge SB, Greene FL, et al., eds.: AJCC Cancer Staging Manual. 8th ed. New York, NY: Springer, 2017, pp. 967–72.</entry></Row><Row><entry NameEnd="col5" NameSt="col1"><Superscript>b</Superscript>For skin, <Strong>patch</Strong> indicates any size skin lesion without significant elevation or induration. Presence/absence of hypo- or hyperpigmentation, scale, crusting, and/or poikiloderma should be noted.</entry></Row><Row><entry NameEnd="col5" NameSt="col1"><Superscript>c</Superscript>For skin, <Strong>plaque</Strong> indicates any size skin lesion that is elevated or indurated. Presence/absence of scale,  crusting, and/or poikiloderma should be noted. Histological features such as folliculotropism, large cell transformation (&gt;25% large cells) and CD30 positivity or negativity, as well as clinical features such as ulceration, are important to document.</entry></Row><Row><entry NameEnd="col5" NameSt="col1"><Superscript>d</Superscript>For blood, Sézary cells are defined as lymphocytes with hyperconvoluted cerebriform nuclei. If Sézary cells cannot be used to determine tumor burden for B2, then one of the following modified ISCL criteria, along with a positive clonal rearrangement of the T-cell receptor (TCR), may be used instead: (1) expanded CD4+ or CD3+ cells with a CD4/CD8 ratio of &gt;10, or (2) expanded CD4+ cells with abnormal immunophenotype, including loss of CD7 (&gt;40%) or CD26 (&gt;30%).</entry></Row><Row><entry NameEnd="col5" NameSt="col1"><Superscript>e</Superscript>A T-cell clone is defined by polymerase chain reaction or Southern blot analysis of the TCR gene.</entry></Row><Row><entry NameEnd="col5" NameSt="col1"><Superscript>f</Superscript>For node, <Strong>abnormal peripheral lymph node(s)</Strong> indicates any palpable peripheral node that on physical examination is firm, irregular, clustered, fixed or ≥1.5 cm in diameter. Node groups examined on physical examination include cervical, supraclavicular, epitrochlear, axillary, and inguinal. Central nodes, which generally are not amenable to pathological assessment, currently are not considered in the nodal classification unless used to establish N3 histopathologically.</entry></Row><Row><entry NameEnd="col5" NameSt="col1"><Superscript>g</Superscript>For skin, <Strong>tumor</Strong> indicates at least one 1-cm diameter solid or nodular lesion with evidence of depth and/or vertical growth. Note the total number of lesions, total volume of lesions, largest size lesion, and region of body involved. Also note whether there is histological evidence of large cell transformation. Phenotyping for CD30 is encouraged.</entry></Row><Row><entry NameEnd="col5" NameSt="col1"><Superscript>h</Superscript>For viscera, spleen and liver may be diagnosed by imaging criteria.</entry></Row></TFoot><TBody><Row><entry MoreRows="6">IVA1</entry><entry MoreRows="6">T1–4, N0–2, M0</entry><entry>See T1‒2 descriptions above in <SummaryRef href="CDR0000062881#_580" url="/types/lymphoma/hp/mycosis-fungoides-treatment-pdq">Table 2</SummaryRef>, Stages IA, IB.</entry><entry MoreRows="6">B2</entry><entry MoreRows="6">B2 = High blood tumor burden: ≥1,000 mcg/L 
Sézary cells<Superscript>d</Superscript> or &gt;40% CD4+/CD7- or increased &gt;30% CD4+/CD26- cells with positive clone.<Superscript>e</Superscript>
</entry></Row><Row><entry>T3 = One or more tumors<Superscript>g</Superscript> (≥1 cm in diameter).</entry></Row><Row><entry>–T3a = Multiple lesions involving 2  noncontiguous body regions.</entry></Row><Row><entry>–T3b = Multiple lesions involving ≥3 body regions.</entry></Row><Row><entry>T4 = Confluence of erythema covering ≥80% of body surface area.</entry></Row><Row><entry>See N0–2 descriptions above in  <SummaryRef href="CDR0000062881#_581" url="/types/lymphoma/hp/mycosis-fungoides-treatment-pdq">Table 3</SummaryRef>, Stages IIA, IIB.</entry></Row><Row><entry>M0 = No visceral organ involvement.</entry></Row><Row><entry MoreRows="2">IVA2 </entry><entry MoreRows="2">T1–4, N3, M0</entry><entry>See T1‒2 descriptions above in <SummaryRef href="CDR0000062881#_580" url="/types/lymphoma/hp/mycosis-fungoides-treatment-pdq">Table 2</SummaryRef>,  Stages IA, IB and see T3–4 descriptions above in this table, Stage IVA1.</entry><entry MoreRows="2">B0–2</entry><entry MoreRows="2">See B0, B1 descriptions above in <SummaryRef href="CDR0000062881#_580" url="/types/lymphoma/hp/mycosis-fungoides-treatment-pdq">Table 2</SummaryRef>, Stage IA and see B2 description above in this table, Stage IVA1.</entry></Row><Row><entry>N3 = Clinically abnormal peripheral lymph nodes; histopathology Dutch grades 3–4 or NCI LN4; clone positive or negative.</entry></Row><Row><entry>M0 = No visceral organ involvement.</entry></Row><Row><entry MoreRows="3">IVB</entry><entry MoreRows="3">T1–4, N0–3, M1</entry><entry>See T1‒2 descriptions above in <SummaryRef href="CDR0000062881#_580" url="/types/lymphoma/hp/mycosis-fungoides-treatment-pdq">Table 2</SummaryRef>,  Stages IA, IB and see T3–4 descriptions above in this table, Stage IVA1.</entry><entry MoreRows="3">B0–2</entry><entry MoreRows="3">See B0, B1 descriptions above in <SummaryRef href="CDR0000062881#_580" url="/types/lymphoma/hp/mycosis-fungoides-treatment-pdq">Table 2</SummaryRef>, Stage IA and see B2 description above in this table, Stage IVA1.</entry></Row><Row><entry>See N0–2 descriptions above in <SummaryRef href="CDR0000062881#_581" url="/types/lymphoma/hp/mycosis-fungoides-treatment-pdq">Table 3</SummaryRef>, Stages IIA, IIB.</entry></Row><Row><entry>N3 = Clinically abnormal peripheral lymph nodes; histopathology Dutch grades 3–4 or NCI LN4; clone positive or negative.</entry></Row><Row><entry>M1 = Visceral involvement (must have pathology confirmation,<Superscript>h</Superscript> and organ involved should be specified).</entry></Row></TBody></TGroup></Table><ReferenceSection><Citation idx="1">Primary cutaneous lymphomas. In: Amin MB, Edge SB, Greene FL, et al., eds.: AJCC Cancer Staging Manual. 8th ed. Springer; 2017, pp. 967–72.</Citation><Citation idx="2" PMID="17540844">Olsen E, Vonderheid E, Pimpinelli N, et al.: Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 110 (6): 1713-22, 2007.</Citation><Citation idx="3" PMID="20855822">Agar NS, Wedgeworth E, Crichton S, et al.: Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol 28 (31): 4730-9, 2010.</Citation></ReferenceSection></SummarySection><SummarySection id="_50"><SectMetaData><SpecificDiagnosis ref="CDR0000038223">mycosis fungoides/Sezary syndrome</SpecificDiagnosis><SpecificDiagnosis ref="CDR0000043725">cutaneous T-cell non-Hodgkin lymphoma</SpecificDiagnosis><SectionType>Treatment option overview--legacy</SectionType></SectMetaData><Title>Treatment Option Overview for Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas</Title><Para id="_611">Anecdotal responses, some lasting for months, can be seen with aggressive antibiotic treatment of <Emphasis>Staphylococcus aureus</Emphasis>, with corresponding decreased expression of interleukin-2 receptors, STAT signaling, and T-cell proliferation.<Reference refidx="1"/>[<LOERef href="CDR0000810039" dictionary="NotSet" audience="Health professional">Level of evidence C3</LOERef>]</Para><Para id="_132">These types of treatments produce
remissions, but long-term remissions are uncommon.  Treatment is considered palliative for most patients,
although major symptomatic improvement is regularly achieved.  Survival of more than 8 years  is common for patients with early stages of disease.  All patients with cutaneous T-cell lymphomas are
candidates for clinical trials evaluating new approaches to treatment.
</Para><Table id="_702"><Title>Table 6.  Treatment Options for Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas</Title><TGroup Cols="2"><ColSpec ColName="col1" ColNum="1" ColWidth="49.26%"/><ColSpec ColName="col2" ColNum="2" ColWidth="50.73%"/><THead><Row><entry Align="Center">Stage (<SummaryRef href="CDR0000062881#_10" url="/types/lymphoma/hp/mycosis-fungoides-treatment-pdq">TNM Definitions</SummaryRef>)</entry><entry Align="Center">Treatment Options</entry></Row></THead><TBody><Row><entry MoreRows="5">Stage I and Stage II Mycosis Fungoides</entry><entry><SummaryRef href="CDR0000062881#_620" url="/types/lymphoma/hp/mycosis-fungoides-treatment-pdq">Photodynamic therapy</SummaryRef></entry></Row><Row><entry><SummaryRef href="CDR0000062881#_622" url="/types/lymphoma/hp/mycosis-fungoides-treatment-pdq">Radiation therapy</SummaryRef></entry></Row><Row><entry><SummaryRef href="CDR0000062881#_624" url="/types/lymphoma/hp/mycosis-fungoides-treatment-pdq">Biological therapy</SummaryRef></entry></Row><Row><entry><SummaryRef href="CDR0000062881#_626" url="/types/lymphoma/hp/mycosis-fungoides-treatment-pdq">Chemotherapy</SummaryRef></entry></Row><Row><entry><SummaryRef href="CDR0000062881#_628" url="/types/lymphoma/hp/mycosis-fungoides-treatment-pdq">Other drug therapy</SummaryRef></entry></Row><Row><entry><SummaryRef href="CDR0000062881#_630" url="/types/lymphoma/hp/mycosis-fungoides-treatment-pdq">Targeted therapy</SummaryRef></entry></Row><Row><entry MoreRows="6">Stage III and Stage IV Mycosis Fungoides and Sézary Syndrome</entry><entry><SummaryRef href="CDR0000062881#_648" url="/types/lymphoma/hp/mycosis-fungoides-treatment-pdq">Photodynamic therapy</SummaryRef></entry></Row><Row><entry><SummaryRef href="CDR0000062881#_650" url="/types/lymphoma/hp/mycosis-fungoides-treatment-pdq">Radiation therapy</SummaryRef></entry></Row><Row><entry><SummaryRef href="CDR0000062881#_652" url="/types/lymphoma/hp/mycosis-fungoides-treatment-pdq">Biological therapy</SummaryRef></entry></Row><Row><entry><SummaryRef href="CDR0000062881#_654" url="/types/lymphoma/hp/mycosis-fungoides-treatment-pdq">Chemotherapy</SummaryRef></entry></Row><Row><entry><SummaryRef href="CDR0000062881#_656" url="/types/lymphoma/hp/mycosis-fungoides-treatment-pdq">Other drug therapy</SummaryRef></entry></Row><Row><entry><SummaryRef href="CDR0000062881#_658" url="/types/lymphoma/hp/mycosis-fungoides-treatment-pdq">Targeted therapy</SummaryRef></entry></Row><Row><entry><SummaryRef href="CDR0000062881#_660" url="/types/lymphoma/hp/mycosis-fungoides-treatment-pdq">Checkpoint inhibitors</SummaryRef></entry></Row><Row><entry MoreRows="6">Recurrent Mycosis Fungoides and Sézary Syndrome</entry><entry><SummaryRef href="CDR0000062881#_666" url="/types/lymphoma/hp/mycosis-fungoides-treatment-pdq">Radiation therapy</SummaryRef></entry></Row><Row><entry><SummaryRef href="CDR0000062881#_668" url="/types/lymphoma/hp/mycosis-fungoides-treatment-pdq">Photodynamic therapy</SummaryRef></entry></Row><Row><entry><SummaryRef href="CDR0000062881#_670" url="/types/lymphoma/hp/mycosis-fungoides-treatment-pdq">Chemotherapy</SummaryRef></entry></Row><Row><entry><SummaryRef href="CDR0000062881#_672" url="/types/lymphoma/hp/mycosis-fungoides-treatment-pdq">Other drug therapy</SummaryRef></entry></Row><Row><entry><SummaryRef href="CDR0000062881#_674" url="/types/lymphoma/hp/mycosis-fungoides-treatment-pdq">Biological therapy</SummaryRef></entry></Row><Row><entry><SummaryRef href="CDR0000062881#_676" url="/types/lymphoma/hp/mycosis-fungoides-treatment-pdq">Allogeneic stem cell transplant</SummaryRef></entry></Row><Row><entry><SummaryRef href="CDR0000062881#_678" url="/types/lymphoma/hp/mycosis-fungoides-treatment-pdq">Targeted therapy</SummaryRef></entry></Row><Row><entry MoreRows="2">Primary Cutaneous Anaplastic Large Cell Lymphoma</entry><entry>Radiation therapy</entry></Row><Row><entry>Targeted therapy</entry></Row><Row><entry>Chemotherapy</entry></Row><Row><entry MoreRows="3">Subcutaneous Panniculitis-Like T-Cell Lymphoma</entry><entry>Immunosuppression</entry></Row><Row><entry>Chemotherapy</entry></Row><Row><entry>Targeted therapy</entry></Row><Row><entry>Allogeneic stem cell transplant</entry></Row><Row><entry MoreRows="1">Primary Cutaneous Gamma Delta T-Cell Lymphoma</entry><entry>Chemotherapy</entry></Row><Row><entry>Allogeneic stem cell transplant</entry></Row><Row><entry MoreRows="1">Primary Cutaneous Aggressive Epidermotropic CD8-Positive T-Cell Lymphoma</entry><entry>Chemotherapy</entry></Row><Row><entry>Allogeneic stem cell transplant</entry></Row></TBody></TGroup></Table><ReferenceSection><Citation idx="1" PMID="31331920">Lindahl LM, Willerslev-Olsen A, Gjerdrum LMR, et al.: Antibiotics inhibit tumor and disease activity in cutaneous T-cell lymphoma. Blood 134 (13): 1072-1083, 2019.</Citation></ReferenceSection></SummarySection><SummarySection id="_54"><SectMetaData><SpecificDiagnosis ref="CDR0000038224">stage I mycosis fungoides/Sezary syndrome</SpecificDiagnosis><SpecificDiagnosis ref="CDR0000038225">stage II mycosis fungoides/Sezary syndrome</SpecificDiagnosis><SectionType>Treatment options by stage</SectionType></SectMetaData><Title>Treatment of Stage I and Stage II Mycosis Fungoides</Title><Para id="_55">Several forms of treatment can completely resolve skin
lesions at stages I and II, so the choice of therapy depends on local expertise
and the facilities available.  With therapy, the survival of patients with
stage IA disease can be expected to be the same as for age- and sex-matched
controls.<Reference refidx="1"/><Reference refidx="2"/><Reference refidx="3"/>
</Para><Para id="_347">There is no curative therapy and no clear difference in overall survival (OS) among the treatment options for patients with stage I and stage II mycosis fungoides.</Para><Para id="_348">A randomized study of 103 patients compared combined total-skin electron-beam radiation
(TSEB) plus combination chemotherapy with  sequential topical therapies.<Reference refidx="4"/>  In the latter group, combination
chemotherapy was reserved for patients with symptomatic extracutaneous disease or disease
that was refractory to topical therapies.  Patients with any disease stage were eligible. 
Although the complete response rate was higher with combined therapy, toxic
effects were considerably greater,  and no difference was seen in disease-free
survival (DFS) or OS between the two  groups.<Reference refidx="4"/>[<LOERef href="CDR0000810017" dictionary="NotSet" audience="Health professional">Level of evidence A1</LOERef>]

</Para><SummarySection id="_470"><Title>Treatment Options for Stage I and Stage II  Mycosis Fungoides  </Title><Para id="_471">Treatment options for stages I and II  mycosis fungoides include the following:<Reference refidx="5"/>
</Para><OrderedList id="_619" Style="Arabic"><ListItem><SummaryRef href="CDR0000062881#_620" url="/types/lymphoma/hp/mycosis-fungoides-treatment-pdq">Photodynamic therapy</SummaryRef>.</ListItem><ListItem><SummaryRef href="CDR0000062881#_622" url="/types/lymphoma/hp/mycosis-fungoides-treatment-pdq">Radiation therapy</SummaryRef>.</ListItem><ListItem><SummaryRef href="CDR0000062881#_624" url="/types/lymphoma/hp/mycosis-fungoides-treatment-pdq">Biological therapy</SummaryRef>.</ListItem><ListItem><SummaryRef href="CDR0000062881#_626" url="/types/lymphoma/hp/mycosis-fungoides-treatment-pdq">Chemotherapy</SummaryRef>.</ListItem><ListItem><SummaryRef href="CDR0000062881#_628" url="/types/lymphoma/hp/mycosis-fungoides-treatment-pdq">Other drug therapy</SummaryRef>.</ListItem><ListItem><SummaryRef href="CDR0000062881#_630" url="/types/lymphoma/hp/mycosis-fungoides-treatment-pdq">Targeted therapy</SummaryRef>.</ListItem></OrderedList><SummarySection id="_620"><Title>Photodynamic therapy</Title><OrderedList id="_631" Style="Arabic"><ListItem>Psoralen and ultraviolet A (PUVA) radiation therapy.<Reference refidx="6"/><Reference refidx="7"/><Reference refidx="8"/><Reference refidx="9"/><Reference refidx="10"/><Reference refidx="11"/><ItemizedList id="_632" Style="bullet"><ListItem>Therapeutic trials with PUVA
have shown an 80% to 90% complete remission rate in patients, with those in early cutaneous stages
achieving the best responses.  PUVA may be used in conjunction with systemic
treatment.<Reference refidx="10"/>  Continued maintenance therapy with PUVA at more
protracted intervals is generally required to prolong remission duration.<Reference refidx="6"/><Reference refidx="7"/><Reference refidx="8"/><Reference refidx="10"/> 
PUVA combined with interferon alfa-2a is associated with a high response 
rate.<Reference refidx="9"/><Reference refidx="10"/></ListItem></ItemizedList></ListItem><ListItem>Narrowband ultraviolet B radiation.<Reference refidx="12"/><Reference refidx="13"/><ItemizedList id="_633" Style="bullet"><ListItem>Single-arm and retrospective comparisons confirm the efficacy of narrowband ultraviolet B with 80% to 90% complete remission rates, especially for patients with early cutaneous stages.<Reference refidx="12"/><Reference refidx="13"/></ListItem><ListItem>A Cochrane systematic review and meta-analysis compared PUVA with narrowband ultraviolet B radiation in 778 patients with early-stage mycosis fungoides (stage IA, IB, and IIA). Significantly higher complete responses were seen in patients treated with PUVA (73.8% vs. 62.2%; hazard ratio, 1.68; 95% confidence interval [CI], 1.02–2.76; <Emphasis>P</Emphasis> = .04). There were no significant differences in adverse effects.<Reference refidx="11"/>[<LOERef href="CDR0000810031" dictionary="NotSet" audience="Health professional">Level of evidence B3</LOERef>]</ListItem></ItemizedList></ListItem></OrderedList></SummarySection><SummarySection id="_622"><Title>Radiation therapy</Title><OrderedList id="_634" Style="Arabic"><ListItem>TSEB.<Reference refidx="14"/><Reference refidx="15"/><Reference refidx="16"/><Reference refidx="17"/><Reference refidx="18"/><Reference refidx="19"/><ItemizedList id="_635" Style="bullet"><ListItem>Electron-beam radiation therapy of
appropriate energies will penetrate only to the dermis, and thus, the skin alone
can be treated without systemic effects.  This therapy requires a
radiation therapy facility with physics support and considerable
technical expertise to deliver precise dosimetry. TSEB can result in short- and long-term cutaneous
toxic effects and is not widely available.  </ListItem><ListItem>This therapy can provide excellent palliation, with
complete response rates as high as  80%, and may be combined with systemic treatment. Based on the long-term survival of
these early-stage patients, electron-beam radiation therapy is sometimes used with 
curative intent.<Reference refidx="14"/><Reference refidx="15"/><Reference refidx="16"/><Reference refidx="17"/><Reference refidx="18"/>  Long-term DFS can be achieved in
patients with unilesional mycosis fungoides treated with local radiation
therapy.<Reference refidx="19"/></ListItem></ItemizedList></ListItem><ListItem>Local electron-beam radiation or orthovoltage radiation therapy may be
used to palliate areas of bulky or symptomatic skin disease.<Reference refidx="20"/><Reference refidx="21"/></ListItem></OrderedList></SummarySection><SummarySection id="_624"><Title>Biological therapy</Title><OrderedList id="_636" Style="Arabic"><ListItem>Interferon alfa
or interferon gamma alone or in combination with topical therapy.<Reference refidx="22"/><Reference refidx="23"/>[<LOERef href="CDR0000810039" dictionary="NotSet" audience="Health professional">Level of evidence C3</LOERef>]<ItemizedList id="_637" Style="bullet"><ListItem>A retrospective review of 198 patients with mycosis fungoides and Sézary syndrome compared the time-to-next-treatment (TTNT) between patients who received interferon alfa and conventional chemotherapy. Interferon alfa provided a longer TTNT of 8.7 months (95% CI, 6.0–18.0) than did chemotherapy, with a TTNT of 3.9 months (95% CI, 3.2–5.1) (<Emphasis>P</Emphasis> &lt; .00001).<Reference refidx="23"/>[<LOERef href="CDR0000810039" dictionary="NotSet" audience="Health professional">Level of evidence C3</LOERef>]</ListItem></ItemizedList></ListItem></OrderedList></SummarySection><SummarySection id="_626"><Title>Chemotherapy</Title><Para id="_705">Chemotherapeutic agents generally demonstrate short durations of response.  In a retrospective review of 198 patients with advanced-stage disease, the median TTNT was 4 months.<Reference refidx="23"/> However,  these comparisons may be confounded by the order in which the agents were introduced.</Para><OrderedList id="_638" Style="Arabic"><ListItem>Topical
chemotherapy with mechlorethamine.<Reference refidx="14"/><Reference refidx="24"/><Reference refidx="25"/><ItemizedList id="_639" Style="bullet"><ListItem>This form of treatment may be
used palliatively or to supplement therapeutic approaches directed against
nodal or visceral disease.  Topical application of
mechlorethamine has produced regression of cutaneous lesions, with particular
efficacy in early stages of disease.  The overall complete remission rate is
related to skin stage; 50% to 80% of TNM classification T1 patients, 25% to 75% of
T2 patients, as many as  50% of T3
patients, and 20% to 40% of T4 patients  have complete responses.  The overall complete remission rate in 243 patients
was 64% and was related to stage; as many as 35% of stage IV patients had complete
responses. Treatments are usually continued for 2 to
3 years.  Continuous 5-year DFS may be possible in  as many as 33% of T1 patients.<Reference refidx="14"/><Reference refidx="24"/><Reference refidx="25"/></ListItem></ItemizedList></ListItem><ListItem>Oral methotrexate (<ProtocolRef nct_id="NCT00425555">NCT00425555</ProtocolRef>).<Reference refidx="26"/></ListItem><ListItem>Pegylated liposomal doxorubicin.<Reference refidx="27"/><Reference refidx="28"/><Reference refidx="29"/></ListItem><ListItem>Fludarabine, cladribine, and pentostatin are active agents for
mycosis fungoides.<Reference refidx="30"/><Reference refidx="31"/><Reference refidx="32"/><Reference refidx="33"/></ListItem><ListItem>Single-agent chemotherapy or combination systemic chemotherapy (chlorambucil plus prednisone, mechlorethamine,
cyclophosphamide, methotrexate) is often combined with
treatment directed at the skin.<Reference refidx="4"/><Reference refidx="23"/><Reference refidx="34"/><Reference refidx="35"/></ListItem><ListItem>Pralatrexate (folate analogue).<Reference refidx="23"/><Reference refidx="36"/><Reference refidx="37"/></ListItem></OrderedList></SummarySection><SummarySection id="_628"><Title>Other drug therapy</Title><OrderedList id="_643" Style="Arabic"><ListItem>Symptomatic management with topical corticosteroids. Low potency steroids can be used on the face with safety and efficacy.<Reference refidx="38"/></ListItem><ListItem>Bexarotene, an oral or topical retinoid (<ProtocolRef nct_id="NCT00255801">NCT00255801</ProtocolRef>).<Reference refidx="39"/><Reference refidx="40"/></ListItem><ListItem>Lenalidomide.<Reference refidx="41"/></ListItem><ListItem>Vorinostat or romidepsin or other histone deacetylase inhibitors (HDACi).<Reference refidx="23"/><Reference refidx="42"/><Reference refidx="43"/><Reference refidx="44"/>[<LOERef href="CDR0000810039" dictionary="NotSet" audience="Health professional">Level of evidence C3</LOERef>]<ItemizedList id="_644" Style="bullet"><ListItem>A retrospective review of 198 patients with mycosis fungoides and Sézary syndrome compared TTNT between HDACi and conventional chemotherapy. HDACi provided a longer TTNT of 4.5 months (95% CI, 4.0–6.1) than did chemotherapy, with a TTNT of 3.9 months (95% CI, 3.2–5.1; <Emphasis>P</Emphasis> = .01).<Reference refidx="23"/>[<LOERef href="CDR0000810039" dictionary="NotSet" audience="Health professional">Level of evidence C3</LOERef>]</ListItem></ItemizedList></ListItem></OrderedList></SummarySection><SummarySection id="_630"><Title>Targeted therapy</Title><OrderedList id="_645" Style="Arabic"><ListItem>Brentuximab vedotin.<Reference refidx="45"/><Reference refidx="46"/><ItemizedList id="_646" Style="bullet"><ListItem>Two phase II trials of 58 patients with variable CD30 expression showed a 50% to 70% response rate with 50% of patients still in remission after 1 year.<Reference refidx="45"/><Reference refidx="46"/>[<LOERef href="CDR0000810039" dictionary="NotSet" audience="Health professional">Level of evidence C3</LOERef>] </ListItem></ItemizedList></ListItem></OrderedList></SummarySection></SummarySection><SummarySection id="_TrialSearch_54_sid_5"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_54_22">Use our <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials-search/advanced">advanced clinical trial search</ExternalRef> to find NCI-supported cancer clinical trials that are now enrolling patients. The search can be narrowed by location of the trial, type of treatment, name of the drug, and other criteria. <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials">General information</ExternalRef> about clinical trials is also available.</Para></SummarySection><ReferenceSection><Citation idx="1" PMID="8915308" MedlineID="97072542">Kim YH, Jensen RA, Watanabe GL, et al.: Clinical stage IA (limited patch and plaque) mycosis fungoides. A long-term outcome analysis. Arch Dermatol 132 (11): 1309-13, 1996.</Citation><Citation idx="2" PMID="10071312" MedlineID="99168870">Zackheim HS, Amin S, Kashani-Sabet M, et al.: Prognosis in cutaneous T-cell lymphoma by skin stage: long-term survival in 489 patients. J Am Acad Dermatol 40 (3): 418-25, 1999.</Citation><Citation idx="3" PMID="24713743">Vollmer RT: A review of survival in mycosis fungoides. Am J Clin Pathol 141 (5): 706-11, 2014.</Citation><Citation idx="4" PMID="2594037" MedlineID="90081777">Kaye FJ, Bunn PA, Steinberg SM, et al.: A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med 321 (26): 1784-90, 1989.</Citation><Citation idx="5" PMID="16574401">Trautinger F, Knobler R, Willemze R, et al.: EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome. Eur J Cancer 42 (8): 1014-30, 2006.</Citation><Citation idx="6" PMID="7622650" MedlineID="95348292">Herrmann JJ, Roenigk HH, Hurria A, et al.: Treatment of mycosis fungoides with photochemotherapy (PUVA): long-term follow-up. J Am Acad Dermatol 33 (2 Pt 1): 234-42, 1995.</Citation><Citation idx="7" PMID="1626959" MedlineID="92328537">Ramsay DL, Lish KM, Yalowitz CB, et al.: Ultraviolet-B phototherapy for early-stage cutaneous T-cell lymphoma. Arch Dermatol 128 (7): 931-3, 1992.</Citation><Citation idx="8" PMID="15781671">Querfeld C, Rosen ST, Kuzel TM, et al.: Long-term follow-up of patients with early-stage cutaneous T-cell lymphoma who achieved complete remission with psoralen plus UV-A monotherapy. Arch Dermatol 141 (3): 305-11, 2005.</Citation><Citation idx="9" PMID="7799028" MedlineID="95096954">Kuzel TM, Roenigk HH, Samuelson E, et al.: Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fungoides and the Sézary syndrome. J Clin Oncol 13 (1): 257-63, 1995.</Citation><Citation idx="10" PMID="26547257">Olsen EA, Hodak E, Anderson T, et al.: Guidelines for phototherapy of mycosis fungoides and Sézary syndrome: A consensus statement of the United States Cutaneous Lymphoma Consortium. J Am Acad Dermatol 74 (1): 27-58, 2016.</Citation><Citation idx="11" PMID="30698622">Phan K, Ramachandran V, Fassihi H, et al.: Comparison of Narrowband UV-B With Psoralen-UV-A Phototherapy for Patients With Early-Stage Mycosis Fungoides: A Systematic Review and Meta-analysis. JAMA Dermatol 155 (3): 335-341, 2019.</Citation><Citation idx="12" PMID="28711574">Almohideb M, Walsh S, Walsh S, et al.: Bath Psoralen-ultraviolet A and Narrowband Ultraviolet B Phototherapy as Initial Therapy for Early-stage Mycosis Fungoides: A Retrospective Cohort of 267 Cases at the University of Toronto. Clin Lymphoma Myeloma Leuk 17 (9): 604-612, 2017.</Citation><Citation idx="13" PMID="23030414">Elcin G, Duman N, Karahan S, et al.: Long-term follow-up of early mycosis fungoides patients treated with narrowband ultraviolet B phototherapy. J Dermatolog Treat 25 (3): 268-73, 2014.</Citation><Citation idx="14" PMID="10192339" MedlineID="99206557">Chinn DM, Chow S, Kim YH, et al.: Total skin electron beam therapy with or without adjuvant topical nitrogen mustard or nitrogen mustard alone as initial treatment of T2 and T3 mycosis fungoides. Int J Radiat Oncol Biol Phys 43 (5): 951-8, 1999.</Citation><Citation idx="15" PMID="9276369" MedlineID="97420384">Quirós PA, Jones GW, Kacinski BM, et al.: Total skin electron beam therapy followed by adjuvant psoralen/ultraviolet-A light in the management of patients with T1 and T2 cutaneous T-cell lymphoma (mycosis fungoides). Int J Radiat Oncol Biol Phys 38 (5): 1027-35, 1997.</Citation><Citation idx="16" PMID="15001254">Ysebaert L, Truc G, Dalac S, et al.: Ultimate results of radiation therapy for T1-T2 mycosis fungoides (including reirradiation). Int J Radiat Oncol Biol Phys 58 (4): 1128-34, 2004.</Citation><Citation idx="17" PMID="10223240" MedlineID="99237751">Jones GW, Rosenthal D, Wilson LD: Total skin electron radiation for patients with erythrodermic cutaneous T-cell lymphoma (mycosis fungoides and the Sézary syndrome). Cancer 85 (9): 1985-95, 1999.</Citation><Citation idx="18" PMID="21576575">Navi D, Riaz N, Levin YS, et al.: The Stanford University experience with conventional-dose, total skin electron-beam therapy in the treatment of generalized patch or plaque (T2) and tumor (T3) mycosis fungoides. Arch Dermatol 147 (5): 561-7, 2011.</Citation><Citation idx="19" PMID="9788416" MedlineID="99002465">Micaily B, Miyamoto C, Kantor G, et al.: Radiotherapy for unilesional mycosis fungoides. Int J Radiat Oncol Biol Phys 42 (2): 361-4, 1998.</Citation><Citation idx="20" PMID="22818412">Thomas TO, Agrawal P, Guitart J, et al.: Outcome of patients treated with a single-fraction dose of palliative radiation for cutaneous T-cell lymphoma. Int J Radiat Oncol Biol Phys 85 (3): 747-53, 2013.</Citation><Citation idx="21" PMID="31636100">O'Malley JT, de Masson A, Lowry EL, et al.: Radiotherapy Eradicates Malignant T Cells and Is Associated with Improved Survival in Early-Stage Mycosis Fungoides. Clin Cancer Res 26 (2): 408-418, 2020.</Citation><Citation idx="22" PMID="8522486" MedlineID="96087568">Olsen EA, Bunn PA: Interferon in the treatment of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 9 (5): 1089-107, 1995.</Citation><Citation idx="23" PMID="25336628">Hughes CF, Khot A, McCormack C, et al.: Lack of durable disease control with chemotherapy for mycosis fungoides and Sézary syndrome: a comparative study of systemic therapy. Blood 125 (1): 71-81, 2015.</Citation><Citation idx="24" PMID="23069814">Lessin SR, Duvic M, Guitart J, et al.: Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. JAMA Dermatol 149 (1): 25-32, 2013.</Citation><Citation idx="25" PMID="16172308">de Quatrebarbes J, Estève E, Bagot M, et al.: Treatment of early-stage mycosis fungoides with twice-weekly applications of mechlorethamine and topical corticosteroids: a prospective study. Arch Dermatol 141 (9): 1117-20, 2005.</Citation><Citation idx="26" PMID="14576667">Zackheim HS, Kashani-Sabet M, McMillan A: Low-dose methotrexate to treat mycosis fungoides: a retrospective study in 69 patients. J Am Acad Dermatol 49 (5): 873-8, 2003.</Citation><Citation idx="27" PMID="12942567">Wollina U, Dummer R, Brockmeyer NH, et al.: Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma. Cancer 98 (5): 993-1001, 2003.</Citation><Citation idx="28" PMID="23045580">Dummer R, Quaglino P, Becker JC, et al.: Prospective international multicenter phase II trial of intravenous pegylated liposomal doxorubicin monochemotherapy in patients with stage IIB, IVA, or IVB advanced mycosis fungoides: final results from EORTC 21012. J Clin Oncol 30 (33): 4091-7, 2012.</Citation><Citation idx="29" PMID="18559761">Quereux G, Marques S, Nguyen JM, et al.: Prospective multicenter study of pegylated liposomal doxorubicin treatment in patients with advanced or refractory mycosis fungoides or Sézary syndrome. Arch Dermatol 144 (6): 727-33, 2008.</Citation><Citation idx="30" PMID="1353380" MedlineID="92345592">Saven A, Carrera CJ, Carson DA, et al.: 2-Chlorodeoxyadenosine: an active agent in the treatment of cutaneous T-cell lymphoma. Blood 80 (3): 587-92, 1992.</Citation><Citation idx="31" PMID="1453206" MedlineID="93085392">Foss FM, Ihde DC, Breneman DL, et al.: Phase II study of pentostatin and intermittent high-dose recombinant interferon alfa-2a in advanced mycosis fungoides/Sézary syndrome. J Clin Oncol 10 (12): 1907-13, 1992.</Citation><Citation idx="32" PMID="7931473" MedlineID="95016867">Foss FM, Ihde DC, Linnoila IR, et al.: Phase II trial of fludarabine phosphate and interferon alfa-2a in advanced mycosis fungoides/Sézary syndrome. J Clin Oncol 12 (10): 2051-9, 1994.</Citation><Citation idx="33" PMID="10506607" MedlineID="99438177">Kurzrock R, Pilat S, Duvic M: Pentostatin therapy of T-cell lymphomas with cutaneous manifestations. J Clin Oncol 17 (10): 3117-21, 1999.</Citation><Citation idx="34" PMID="8522487" MedlineID="96087569">Rosen ST, Foss FM: Chemotherapy for mycosis fungoides and the Sézary syndrome. Hematol Oncol Clin North Am 9 (5): 1109-16, 1995.</Citation><Citation idx="35" PMID="2808792" MedlineID="90037735">Zackheim HS, Epstein EH: Low-dose methotrexate for the Sézary syndrome. J Am Acad Dermatol 21 (4 Pt 1): 757-62, 1989.</Citation><Citation idx="36" PMID="22394596">Horwitz SM, Kim YH, Foss F, et al.: Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood 119 (18): 4115-22, 2012.</Citation><Citation idx="37" PMID="24589156">Talpur R, Thompson A, Gangar P, et al.: Pralatrexate alone or in combination with bexarotene: long-term tolerability in relapsed/refractory mycosis fungoides. Clin Lymphoma Myeloma Leuk 14 (4): 297-304, 2014.</Citation><Citation idx="38" PMID="30993584">Duffy R, Jennings T, Kartan S, et al.: Special Considerations in the Treatment of Mycosis Fungoides. Am J Clin Dermatol 20 (4): 571-578, 2019.</Citation><Citation idx="39" PMID="11331325" MedlineID="21229775">Duvic M, Hymes K, Heald P, et al.: Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol 19 (9): 2456-71, 2001.</Citation><Citation idx="40" PMID="14576658">Heald P, Mehlmauer M, Martin AG, et al.: Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial. J Am Acad Dermatol 49 (5): 801-15, 2003.</Citation><Citation idx="41" PMID="24335103">Querfeld C, Rosen ST, Guitart J, et al.: Results of an open-label multicenter phase 2 trial of lenalidomide monotherapy in refractory mycosis fungoides and Sézary syndrome. Blood 123 (8): 1159-66, 2014.</Citation><Citation idx="42" PMID="22981498">Duvic M, Dummer R, Becker JC, et al.: Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: results of a phase II trial. Eur J Cancer 49 (2): 386-94, 2013.</Citation><Citation idx="43" PMID="17577020">Olsen EA, Kim YH, Kuzel TM, et al.: Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 25 (21): 3109-15, 2007.</Citation><Citation idx="44" PMID="19826128">Piekarz RL, Frye R, Turner M, et al.: Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 27 (32): 5410-7, 2009.</Citation><Citation idx="45" PMID="26195720">Kim YH, Tavallaee M, Sundram U, et al.: Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project. J Clin Oncol 33 (32): 3750-8, 2015.</Citation><Citation idx="46" PMID="26261247">Duvic M, Tetzlaff MT, Gangar P, et al.: Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis. J Clin Oncol 33 (32): 3759-65, 2015.</Citation></ReferenceSection></SummarySection><SummarySection id="_73"><SectMetaData><SpecificDiagnosis ref="CDR0000038226">stage III mycosis fungoides/Sezary syndrome</SpecificDiagnosis><SpecificDiagnosis ref="CDR0000038227">stage IV mycosis fungoides/Sezary syndrome</SpecificDiagnosis><SectionType>Treatment options by stage</SectionType></SectMetaData><Title>Treatment of Stage III and Stage IV  Mycosis Fungoides and Sézary Syndrome </Title><Para id="_566"><Strong> Mycosis Fungoides </Strong></Para><Para id="_75">There is no curative therapy and no clear difference in overall survival (OS) among the treatment options for patients with stage III and stage IV disease.</Para><Para id="_354">The use of single alkylating agents has produced objective responses in 60% of
patients, with a duration of less than 6 months.  One of the alkylating agents
(e.g., mechlorethamine, cyclophosphamide, or chlorambucil) or the antimetabolite
methotrexate is the most frequently used.  Single agents have not cured any patients, and insufficient data exist to determine whether these
agents prolong survival.  Combination chemotherapy is not definitely superior
to single agents.  Even in patients with stage IV disease, treatments directed at the skin
may provide significant palliation.  
</Para><Para id="_76">A randomized study of 103 patients compared combined total-skin electron-beam radiation
(TSEB) plus combination chemotherapy with conservation therapy consisting of
sequential topical therapies.<Reference refidx="1"/>  In the latter group, combination
chemotherapy was reserved for patients with symptomatic extracutaneous disease or disease
that was refractory to topical therapies.  Patients with any disease stage were eligible. 
Although the complete response rate was higher with combined therapy, toxic
effects were considerably greater, and no difference was seen in disease-free survival
(DFS) or OS between the two groups.<Reference refidx="1"/>[<LOERef href="CDR0000810017" dictionary="NotSet" audience="Health professional">Level of evidence A1</LOERef>]
</Para><Para id="_535"><Strong>Sézary Syndrome </Strong></Para><Para id="_552">Sézary syndrome is a rare leukemic variant of cutaneous T-cell lymphoma. It is characterized by erythroderma, circulating Sézary cells with cerebriform nuclei, lymphadenopathy, and pruritus.<Reference refidx="2"/> This condition typically progresses rapidly, with only a short duration of response to most therapies. A retrospective review of 176 patients with Sézary syndrome identified the following poor prognostic factors:<Reference refidx="3"/></Para><ItemizedList id="_553" Style="bullet">
     <ListItem>High lactate dehydrogenase.</ListItem><ListItem>Previous diagnosis of mycosis fungoides.</ListItem><ListItem>Presence of T-cell receptor gene rearrangements in skin, blood, or both.</ListItem></ItemizedList><Para id="_526">Remissions attained by using extracorporeal photophoresis, interferon alfa, or retinoids may be followed by allogeneic stem cell transplant. In an anecdotal series of 16 patients with Sézary syndrome after allogeneic transplant, 9 were in complete remission after 4 years.<Reference refidx="4"/></Para><SummarySection id="_484"><Title>Treatment Options for Stage III and Stage IV Mycosis Fungoides and Sézary Syndrome</Title><Para id="_485">Treatment options for stages III and IV  mycosis fungoides and Sézary syndrome include the following (note that in this clinical setting, the skin is
easily injured; any of the topical therapies must be administered with extreme
caution):<Reference refidx="2"/><Reference refidx="5"/></Para><OrderedList id="_647" Style="Arabic"><ListItem><SummaryRef href="CDR0000062881#_648" url="/types/lymphoma/hp/mycosis-fungoides-treatment-pdq">Photodynamic therapy</SummaryRef>.</ListItem><ListItem><SummaryRef href="CDR0000062881#_650" url="/types/lymphoma/hp/mycosis-fungoides-treatment-pdq">Radiation therapy</SummaryRef>.</ListItem><ListItem><SummaryRef href="CDR0000062881#_652" url="/types/lymphoma/hp/mycosis-fungoides-treatment-pdq">Biological therapy</SummaryRef>.</ListItem><ListItem><SummaryRef href="CDR0000062881#_654" url="/types/lymphoma/hp/mycosis-fungoides-treatment-pdq">Chemotherapy</SummaryRef>.</ListItem><ListItem><SummaryRef href="CDR0000062881#_656" url="/types/lymphoma/hp/mycosis-fungoides-treatment-pdq">Other drug therapy</SummaryRef>.</ListItem><ListItem><SummaryRef href="CDR0000062881#_658" url="/types/lymphoma/hp/mycosis-fungoides-treatment-pdq">Targeted therapy</SummaryRef>.</ListItem><ListItem><SummaryRef href="CDR0000062881#_660" url="/types/lymphoma/hp/mycosis-fungoides-treatment-pdq">Checkpoint inhibitors</SummaryRef>.</ListItem></OrderedList><SummarySection id="_648"><Title>Photodynamic therapy</Title><OrderedList id="_649" Style="Arabic"><ListItem>Psoralen and ultraviolet A (PUVA) radiation therapy.<Reference refidx="6"/><Reference refidx="7"/><Reference refidx="8"/><Reference refidx="9"/><Reference refidx="10"/><Reference refidx="11"/><ItemizedList id="_662" Style="bullet"><ListItem>Therapeutic trials with PUVA
have shown an 80% to 90% complete remission rate in patients, with those in early cutaneous stages
achieving the best responses.  PUVA may be used in conjunction with systemic
treatment.<Reference refidx="10"/>  Continued maintenance therapy with PUVA at more
protracted intervals is generally required to prolong remission duration.<Reference refidx="6"/><Reference refidx="7"/><Reference refidx="8"/><Reference refidx="10"/> 
PUVA combined with interferon alfa-2a is associated with a high response 
rate.<Reference refidx="9"/><Reference refidx="10"/></ListItem></ItemizedList></ListItem><ListItem>Narrowband ultraviolet B radiation.<Reference refidx="12"/><Reference refidx="13"/><ItemizedList id="_663" Style="bullet"><ListItem>Single-arm and retrospective comparisons confirm the efficacy of  narrowband ultraviolet B with 80% to 90% complete remission rates, especially for patients with early cutaneous stages.<Reference refidx="12"/><Reference refidx="13"/></ListItem><ListItem>A Cochrane systematic review and meta-analysis compared PUVA with narrowband ultraviolet B radiation in 778 patients with early-stage mycosis fungoides (stage IA, IB, and IIA). Significantly higher complete responses were seen in patients treated with PUVA (73.8% vs. 62.2%; hazard ratio, 1.68; 95% confidence interval [CI], 1.02–2.76; <Emphasis>P</Emphasis> = .04). There were no significant differences in adverse effects.<Reference refidx="11"/>[<LOERef href="CDR0000810031" dictionary="NotSet" audience="Health professional">Level of evidence B3</LOERef>]</ListItem></ItemizedList></ListItem><ListItem>Extracorporeal photophoresis (ECP) alone <Reference refidx="14"/><Reference refidx="15"/><Reference refidx="16"/><Reference refidx="17"/>
or in combination with
TSEB.<Reference refidx="18"/> ECP is particularly applicable for Sézary syndrome and erythrodermic mycosis fungoides.<Reference refidx="17"/><ItemizedList id="_664" Style="bullet"><ListItem>In a retrospective analysis of 65 patients, with a median follow-up of 48 months, use of ECP in the first to third line of treatment yielded a longer median time-to-next treatment (TTNT) than other systemic options (<Emphasis>P</Emphasis> &lt; .03).<Reference refidx="17"/>[<LOERef href="CDR0000810039" dictionary="NotSet" audience="Health professional">Level of evidence C3</LOERef>]</ListItem></ItemizedList></ListItem></OrderedList></SummarySection><SummarySection id="_650"><Title>Radiation therapy</Title><OrderedList id="_651" Style="Arabic"><ListItem>TSEB.<Reference refidx="19"/><Reference refidx="20"/><Reference refidx="21"/><Reference refidx="22"/><Reference refidx="23"/><Reference refidx="24"/><ItemizedList id="_698" Style="bullet"><ListItem>Electron-beam radiation therapy of
appropriate energies will penetrate only to the dermis, and thus, the skin alone
can be treated without systemic effects.  This therapy requires a
radiation therapy facility with physics support and considerable
technical expertise to deliver precise dosimetry. TSEB can result in short- and long-term cutaneous
toxic effects and is not widely available.  </ListItem><ListItem>This therapy can provide excellent palliation, with
complete response rates as high as  80%, and may be combined with systemic treatment. Based on the long-term survival of
these early-stage patients, electron-beam radiation therapy is sometimes used with 
curative intent.<Reference refidx="19"/><Reference refidx="20"/><Reference refidx="21"/><Reference refidx="22"/><Reference refidx="23"/>  Long-term DFS can be achieved in
patients with unilesional mycosis fungoides treated with local radiation
therapy.<Reference refidx="24"/></ListItem></ItemizedList></ListItem><ListItem>Local electron-beam radiation or orthovoltage radiation therapy may 
be used to palliate areas of bulky or symptomatic disease.<Reference refidx="25"/><Reference refidx="26"/></ListItem></OrderedList></SummarySection><SummarySection id="_652"><Title>Biological therapy</Title><OrderedList id="_653" Style="Arabic"><ListItem>Interferon alfa alone or in combination with other agents, such as topical therapy.<Reference refidx="27"/><Reference refidx="28"/><ItemizedList id="_680" Style="bullet"><ListItem>A retrospective review of 198 patients with mycosis fungoides and Sézary syndrome compared the TTNT between patients who received interferon alfa and conventional chemotherapy. Interferon alfa provided a longer TTNT of 8.7 months (95% CI, 6.0–18.0) than did chemotherapy, with a TTNT of 3.9 months (95% CI, 3.2–5.1) (<Emphasis>P</Emphasis> &lt; .00001).<Reference refidx="29"/>[<LOERef href="CDR0000810039" dictionary="NotSet" audience="Health professional">Level of evidence C3</LOERef>]</ListItem></ItemizedList></ListItem></OrderedList></SummarySection><SummarySection id="_654"><Title>Chemotherapy</Title><Para id="_706">Chemotherapeutic agents generally demonstrate short durations of response.  In a retrospective review of 198 patients with advanced-stage disease, the median TTNT was 4 months.<Reference refidx="29"/> However,  these comparisons may be confounded by the order in which the agents were introduced.</Para><OrderedList id="_655" Style="Arabic"><ListItem>Oral methotrexate (<ProtocolRef nct_id="NCT00425555">NCT00425555</ProtocolRef>).<Reference refidx="30"/></ListItem><ListItem>Fludarabine, cladribine, and pentostatin are active agents for
mycosis fungoides and Sézary syndrome.<Reference refidx="27"/><Reference refidx="29"/><Reference refidx="31"/><Reference refidx="32"/><Reference refidx="33"/></ListItem><ListItem>Single-agent chemotherapy  or combination systemic chemotherapy (chlorambucil plus prednisone, mechlorethamine,
cyclophosphamide, methotrexate) often combined with
treatment directed at the skin.<Reference refidx="1"/><Reference refidx="29"/><Reference refidx="34"/><Reference refidx="35"/></ListItem><ListItem>Topical chemotherapy with mechlorethamine.<Reference refidx="36"/><Reference refidx="37"/><ItemizedList id="_683" Style="bullet"><ListItem>This form of treatment may be
used palliatively or to supplement therapeutic approaches directed against
nodal or visceral disease.  Topical application of
mechlorethamine has produced regression of cutaneous lesions, with particular
efficacy in early stages of disease.  The overall complete remission rate is
related to skin stage; 50% to 80% of TNM classification T1 patients, 25% to 75% of
T2 patients, as many as  50% of T3
patients, and 20% to 40% of T4 patients  have complete responses.  The overall complete remission rate in 243 patients
was 64% and was related to stage; as many as 35% of stage IV patients had complete
responses. Treatments are usually continued for 2 to
3 years.  Continuous 5-year DFS may be possible in  as many as 33% of T1 patients.<Reference refidx="19"/><Reference refidx="36"/><Reference refidx="37"/></ListItem></ItemizedList></ListItem><ListItem>Pegylated liposomal doxorubicin.<Reference refidx="38"/><Reference refidx="39"/><Reference refidx="40"/></ListItem><ListItem>Pralatrexate (folate analogue).<Reference refidx="29"/><Reference refidx="41"/><Reference refidx="42"/></ListItem></OrderedList></SummarySection><SummarySection id="_656"><Title>Other drug therapy</Title><OrderedList id="_657" Style="Arabic"><ListItem>Symptomatic management with topical corticosteroids. Low potency steroids can be used on the face with safety and efficacy.<Reference refidx="43"/></ListItem><ListItem>Lenalidomide.<Reference refidx="44"/></ListItem><ListItem>Bexarotene, an oral or topical retinoid.<Reference refidx="45"/><Reference refidx="46"/></ListItem><ListItem>Vorinostat or romidepsin or other  histone deacetylase inhibitors (HDACi).<Reference refidx="2"/><Reference refidx="47"/><Reference refidx="48"/><Reference refidx="49"/><ItemizedList id="_685" Style="bullet"><ListItem>A retrospective review of 198 patients with mycosis fungoides and Sézary syndrome compared TTNT between HDACi and conventional chemotherapy. HDACi provided a longer TTNT of 4.5 months (95% CI, 4.0–6.1) than did chemotherapy, with a TTNT of 3.9 months (95% CI, 3.2–5.1; <Emphasis>P</Emphasis> = .01).<Reference refidx="29"/>[<LOERef href="CDR0000810039" dictionary="NotSet" audience="Health professional">Level of evidence C3</LOERef>]</ListItem></ItemizedList></ListItem></OrderedList></SummarySection><SummarySection id="_658"><Title>Targeted therapy</Title><OrderedList id="_659" Style="Arabic"><ListItem>Brentuximab vedotin.<Reference refidx="50"/><Reference refidx="51"/><ItemizedList id="_686" Style="bullet"><ListItem>Two phase II trials of 58 patients with variable CD30 expression showed a 50% to 70% response rate with 50% of patients still in remission after 1 year.<Reference refidx="50"/><Reference refidx="51"/>[<LOERef href="CDR0000810039" dictionary="NotSet" audience="Health professional">Level of evidence C3</LOERef>] </ListItem></ItemizedList></ListItem></OrderedList></SummarySection><SummarySection id="_660"><Title>Checkpoint inhibitors</Title><OrderedList id="_661" Style="Arabic"><ListItem>Pembrolizumab.<Reference refidx="52"/><ItemizedList id="_699" Style="bullet"><ListItem>Anecdotal responses have been seen in patients with advanced relapsed or refractory mycosis fungoides. In a single-arm, multicenter, phase II trial of 24 patients treated with pembrolizumab, the overall response rate was 38%.<Reference refidx="52"/>[<LOERef href="CDR0000810039" dictionary="NotSet" audience="Health professional">Level of evidence C3</LOERef>]</ListItem><ListItem>There are anecdotal reports of hyperprogression of T-cell malignancies following treatment with immune checkpoint inhibitors.<Reference refidx="53"/><Reference refidx="54"/>
</ListItem></ItemizedList></ListItem></OrderedList></SummarySection></SummarySection><SummarySection id="_TrialSearch_73_sid_6"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_73_22">Use our <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials-search/advanced">advanced clinical trial search</ExternalRef> to find NCI-supported cancer clinical trials that are now enrolling patients. The search can be narrowed by location of the trial, type of treatment, name of the drug, and other criteria. <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials">General information</ExternalRef> about clinical trials is also available.</Para></SummarySection><ReferenceSection><Citation idx="1" PMID="2594037" MedlineID="90081777">Kaye FJ, Bunn PA, Steinberg SM, et al.: A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med 321 (26): 1784-90, 1989.</Citation><Citation idx="2" PMID="21145619">Olsen EA, Rook AH, Zic J, et al.: Sézary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). J Am Acad Dermatol 64 (2): 352-404, 2011.</Citation><Citation idx="3" PMID="22640839">Kubica AW, Davis MD, Weaver AL, et al.: Sézary syndrome: a study of 176 patients at Mayo Clinic. J Am Acad Dermatol 67 (6): 1189-99, 2012.</Citation><Citation idx="4" PMID="25458083">Polansky M, Talpur R, Daulat S, et al.: Long-Term Complete Responses to Combination Therapies and Allogeneic Stem Cell Transplants in Patients With Sézary Syndrome. Clin Lymphoma Myeloma Leuk 15 (5): e83-93, 2015.</Citation><Citation idx="5" PMID="16574401">Trautinger F, Knobler R, Willemze R, et al.: EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome. Eur J Cancer 42 (8): 1014-30, 2006.</Citation><Citation idx="6" PMID="7622650" MedlineID="95348292">Herrmann JJ, Roenigk HH, Hurria A, et al.: Treatment of mycosis fungoides with photochemotherapy (PUVA): long-term follow-up. J Am Acad Dermatol 33 (2 Pt 1): 234-42, 1995.</Citation><Citation idx="7" PMID="1626959" MedlineID="92328537">Ramsay DL, Lish KM, Yalowitz CB, et al.: Ultraviolet-B phototherapy for early-stage cutaneous T-cell lymphoma. Arch Dermatol 128 (7): 931-3, 1992.</Citation><Citation idx="8" PMID="15781671">Querfeld C, Rosen ST, Kuzel TM, et al.: Long-term follow-up of patients with early-stage cutaneous T-cell lymphoma who achieved complete remission with psoralen plus UV-A monotherapy. Arch Dermatol 141 (3): 305-11, 2005.</Citation><Citation idx="9" PMID="7799028" MedlineID="95096954">Kuzel TM, Roenigk HH, Samuelson E, et al.: Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fungoides and the Sézary syndrome. J Clin Oncol 13 (1): 257-63, 1995.</Citation><Citation idx="10" PMID="26547257">Olsen EA, Hodak E, Anderson T, et al.: Guidelines for phototherapy of mycosis fungoides and Sézary syndrome: A consensus statement of the United States Cutaneous Lymphoma Consortium. J Am Acad Dermatol 74 (1): 27-58, 2016.</Citation><Citation idx="11" PMID="30698622">Phan K, Ramachandran V, Fassihi H, et al.: Comparison of Narrowband UV-B With Psoralen-UV-A Phototherapy for Patients With Early-Stage Mycosis Fungoides: A Systematic Review and Meta-analysis. JAMA Dermatol 155 (3): 335-341, 2019.</Citation><Citation idx="12" PMID="28711574">Almohideb M, Walsh S, Walsh S, et al.: Bath Psoralen-ultraviolet A and Narrowband Ultraviolet B Phototherapy as Initial Therapy for Early-stage Mycosis Fungoides: A Retrospective Cohort of 267 Cases at the University of Toronto. Clin Lymphoma Myeloma Leuk 17 (9): 604-612, 2017.</Citation><Citation idx="13" PMID="23030414">Elcin G, Duman N, Karahan S, et al.: Long-term follow-up of early mycosis fungoides patients treated with narrowband ultraviolet B phototherapy. J Dermatolog Treat 25 (3): 268-73, 2014.</Citation><Citation idx="14" PMID="3543674" MedlineID="87115645">Edelson R, Berger C, Gasparro F, et al.: Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results. N Engl J Med 316 (6): 297-303, 1987.</Citation><Citation idx="15" PMID="2191335" MedlineID="90280574">Heald PW, Perez MI, McKiernan G, et al.: Extracorporeal photochemotherapy for CTCL. Prog Clin Biol Res 337: 443-7, 1990.</Citation><Citation idx="16" PMID="18241274">Scarisbrick JJ, Taylor P, Holtick U, et al.: U.K. consensus statement on the use of extracorporeal photopheresis for treatment of cutaneous T-cell lymphoma and chronic graft-versus-host disease. Br J Dermatol 158 (4): 659-78, 2008.</Citation><Citation idx="17" PMID="31467061">Gao C, McCormack C, van der Weyden C, et al.: Prolonged survival with the early use of a novel extracorporeal photopheresis regimen in patients with Sézary syndrome. Blood 134 (16): 1346-1350, 2019.</Citation><Citation idx="18" PMID="2032326" MedlineID="91235394">Palareti G, Maccaferri M, Manotti C, et al.: Fibrinogen assays: a collaborative study of six different methods. C.I.S.M.E.L. Comitato Italiano per la Standardizzazione dei Metodi in Ematologia e Laboratorio. Clin Chem 37 (5): 714-9, 1991.</Citation><Citation idx="19" PMID="10192339" MedlineID="99206557">Chinn DM, Chow S, Kim YH, et al.: Total skin electron beam therapy with or without adjuvant topical nitrogen mustard or nitrogen mustard alone as initial treatment of T2 and T3 mycosis fungoides. Int J Radiat Oncol Biol Phys 43 (5): 951-8, 1999.</Citation><Citation idx="20" PMID="9276369" MedlineID="97420384">Quirós PA, Jones GW, Kacinski BM, et al.: Total skin electron beam therapy followed by adjuvant psoralen/ultraviolet-A light in the management of patients with T1 and T2 cutaneous T-cell lymphoma (mycosis fungoides). Int J Radiat Oncol Biol Phys 38 (5): 1027-35, 1997.</Citation><Citation idx="21" PMID="15001254">Ysebaert L, Truc G, Dalac S, et al.: Ultimate results of radiation therapy for T1-T2 mycosis fungoides (including reirradiation). Int J Radiat Oncol Biol Phys 58 (4): 1128-34, 2004.</Citation><Citation idx="22" PMID="10223240" MedlineID="99237751">Jones GW, Rosenthal D, Wilson LD: Total skin electron radiation for patients with erythrodermic cutaneous T-cell lymphoma (mycosis fungoides and the Sézary syndrome). Cancer 85 (9): 1985-95, 1999.</Citation><Citation idx="23" PMID="21576575">Navi D, Riaz N, Levin YS, et al.: The Stanford University experience with conventional-dose, total skin electron-beam therapy in the treatment of generalized patch or plaque (T2) and tumor (T3) mycosis fungoides. Arch Dermatol 147 (5): 561-7, 2011.</Citation><Citation idx="24" PMID="9788416" MedlineID="99002465">Micaily B, Miyamoto C, Kantor G, et al.: Radiotherapy for unilesional mycosis fungoides. Int J Radiat Oncol Biol Phys 42 (2): 361-4, 1998.</Citation><Citation idx="25" PMID="22818412">Thomas TO, Agrawal P, Guitart J, et al.: Outcome of patients treated with a single-fraction dose of palliative radiation for cutaneous T-cell lymphoma. Int J Radiat Oncol Biol Phys 85 (3): 747-53, 2013.</Citation><Citation idx="26" PMID="31636100">O'Malley JT, de Masson A, Lowry EL, et al.: Radiotherapy Eradicates Malignant T Cells and Is Associated with Improved Survival in Early-Stage Mycosis Fungoides. Clin Cancer Res 26 (2): 408-418, 2020.</Citation><Citation idx="27" PMID="1453206" MedlineID="93085392">Foss FM, Ihde DC, Breneman DL, et al.: Phase II study of pentostatin and intermittent high-dose recombinant interferon alfa-2a in advanced mycosis fungoides/Sézary syndrome. J Clin Oncol 10 (12): 1907-13, 1992.</Citation><Citation idx="28" PMID="8522486" MedlineID="96087568">Olsen EA, Bunn PA: Interferon in the treatment of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 9 (5): 1089-107, 1995.</Citation><Citation idx="29" PMID="25336628">Hughes CF, Khot A, McCormack C, et al.: Lack of durable disease control with chemotherapy for mycosis fungoides and Sézary syndrome: a comparative study of systemic therapy. Blood 125 (1): 71-81, 2015.</Citation><Citation idx="30" PMID="14576667">Zackheim HS, Kashani-Sabet M, McMillan A: Low-dose methotrexate to treat mycosis fungoides: a retrospective study in 69 patients. J Am Acad Dermatol 49 (5): 873-8, 2003.</Citation><Citation idx="31" PMID="1353380" MedlineID="92345592">Saven A, Carrera CJ, Carson DA, et al.: 2-Chlorodeoxyadenosine: an active agent in the treatment of cutaneous T-cell lymphoma. Blood 80 (3): 587-92, 1992.</Citation><Citation idx="32" PMID="7931473" MedlineID="95016867">Foss FM, Ihde DC, Linnoila IR, et al.: Phase II trial of fludarabine phosphate and interferon alfa-2a in advanced mycosis fungoides/Sézary syndrome. J Clin Oncol 12 (10): 2051-9, 1994.</Citation><Citation idx="33" PMID="10506607" MedlineID="99438177">Kurzrock R, Pilat S, Duvic M: Pentostatin therapy of T-cell lymphomas with cutaneous manifestations. J Clin Oncol 17 (10): 3117-21, 1999.</Citation><Citation idx="34" PMID="8522487" MedlineID="96087569">Rosen ST, Foss FM: Chemotherapy for mycosis fungoides and the Sézary syndrome. Hematol Oncol Clin North Am 9 (5): 1109-16, 1995.</Citation><Citation idx="35" PMID="2808792" MedlineID="90037735">Zackheim HS, Epstein EH: Low-dose methotrexate for the Sézary syndrome. J Am Acad Dermatol 21 (4 Pt 1): 757-62, 1989.</Citation><Citation idx="36" PMID="23069814">Lessin SR, Duvic M, Guitart J, et al.: Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. JAMA Dermatol 149 (1): 25-32, 2013.</Citation><Citation idx="37" PMID="16172308">de Quatrebarbes J, Estève E, Bagot M, et al.: Treatment of early-stage mycosis fungoides with twice-weekly applications of mechlorethamine and topical corticosteroids: a prospective study. Arch Dermatol 141 (9): 1117-20, 2005.</Citation><Citation idx="38" PMID="23045580">Dummer R, Quaglino P, Becker JC, et al.: Prospective international multicenter phase II trial of intravenous pegylated liposomal doxorubicin monochemotherapy in patients with stage IIB, IVA, or IVB advanced mycosis fungoides: final results from EORTC 21012. J Clin Oncol 30 (33): 4091-7, 2012.</Citation><Citation idx="39" PMID="12942567">Wollina U, Dummer R, Brockmeyer NH, et al.: Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma. Cancer 98 (5): 993-1001, 2003.</Citation><Citation idx="40" PMID="18559761">Quereux G, Marques S, Nguyen JM, et al.: Prospective multicenter study of pegylated liposomal doxorubicin treatment in patients with advanced or refractory mycosis fungoides or Sézary syndrome. Arch Dermatol 144 (6): 727-33, 2008.</Citation><Citation idx="41" PMID="22394596">Horwitz SM, Kim YH, Foss F, et al.: Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood 119 (18): 4115-22, 2012.</Citation><Citation idx="42" PMID="24589156">Talpur R, Thompson A, Gangar P, et al.: Pralatrexate alone or in combination with bexarotene: long-term tolerability in relapsed/refractory mycosis fungoides. Clin Lymphoma Myeloma Leuk 14 (4): 297-304, 2014.</Citation><Citation idx="43" PMID="30993584">Duffy R, Jennings T, Kartan S, et al.: Special Considerations in the Treatment of Mycosis Fungoides. Am J Clin Dermatol 20 (4): 571-578, 2019.</Citation><Citation idx="44" PMID="24335103">Querfeld C, Rosen ST, Guitart J, et al.: Results of an open-label multicenter phase 2 trial of lenalidomide monotherapy in refractory mycosis fungoides and Sézary syndrome. Blood 123 (8): 1159-66, 2014.</Citation><Citation idx="45" PMID="11331325" MedlineID="21229775">Duvic M, Hymes K, Heald P, et al.: Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol 19 (9): 2456-71, 2001.</Citation><Citation idx="46" PMID="14576658">Heald P, Mehlmauer M, Martin AG, et al.: Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial. J Am Acad Dermatol 49 (5): 801-15, 2003.</Citation><Citation idx="47" PMID="22981498">Duvic M, Dummer R, Becker JC, et al.: Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: results of a phase II trial. Eur J Cancer 49 (2): 386-94, 2013.</Citation><Citation idx="48" PMID="17577020">Olsen EA, Kim YH, Kuzel TM, et al.: Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 25 (21): 3109-15, 2007.</Citation><Citation idx="49" PMID="19826128">Piekarz RL, Frye R, Turner M, et al.: Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 27 (32): 5410-7, 2009.</Citation><Citation idx="50" PMID="26195720">Kim YH, Tavallaee M, Sundram U, et al.: Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project. J Clin Oncol 33 (32): 3750-8, 2015.</Citation><Citation idx="51" PMID="26261247">Duvic M, Tetzlaff MT, Gangar P, et al.: Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis. J Clin Oncol 33 (32): 3759-65, 2015.</Citation><Citation idx="52" PMID="31532724">Khodadoust MS, Rook AH, Porcu P, et al.: Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study. J Clin Oncol 38 (1): 20-28, 2020.</Citation><Citation idx="53" PMID="29768155">Ratner L, Waldmann TA, Janakiram M, et al.: Rapid Progression of Adult T-Cell Leukemia-Lymphoma after PD-1 Inhibitor Therapy. N Engl J Med 378 (20): 1947-1948, 2018.</Citation><Citation idx="54" PMID="35750419">Bennani NN, Kim HJ, Pederson LD, et al.: Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression. J Immunother Cancer 10 (6): , 2022.</Citation></ReferenceSection></SummarySection><SummarySection id="_102"><SectMetaData><SpecificDiagnosis ref="CDR0000038228">recurrent mycosis fungoides/Sezary syndrome</SpecificDiagnosis><SectionType>Treatment options for recurrent cancer</SectionType></SectMetaData><Title>Treatment of Recurrent  Mycosis Fungoides and Sézary Syndrome</Title><Para id="_103">The treatment of patients with relapsed mycosis fungoides  and Sézary syndrome involves the joint decisions of a dermatologist, medical oncologist, and
radiation oncologist.  It may be possible to re-treat localized areas of
relapse in the skin with additional electron-beam radiation therapy or  to repeat total-skin electron-beam radiation therapy (TSEB).<Reference refidx="1"/>  Photon radiation to bulky skin or
nodal masses may prove beneficial.  If these options are not possible, then
continued topical treatment with other modalities, such as mechlorethamine or
psoralen and ultraviolet A radiation (PUVA) may be warranted to relieve
cutaneous symptoms.  
</Para><Para id="_114">Patients should consider clinical trials as a therapeutic
option.</Para><SummarySection id="_498"><Title>Treatment Options for Recurrent Mycosis Fungoides and Sézary Syndrome</Title><Para id="_499">Treatment options under clinical evaluation  for recurrent mycosis fungoides and Sézary syndrome include the following:<Reference refidx="2"/><Reference refidx="3"/></Para><OrderedList id="_665" Style="Arabic"><ListItem><SummaryRef href="CDR0000062881#_666" url="/types/lymphoma/hp/mycosis-fungoides-treatment-pdq">Radiation therapy</SummaryRef>.</ListItem><ListItem><SummaryRef href="CDR0000062881#_668" url="/types/lymphoma/hp/mycosis-fungoides-treatment-pdq">Photodynamic therapy</SummaryRef>.</ListItem><ListItem><SummaryRef href="CDR0000062881#_670" url="/types/lymphoma/hp/mycosis-fungoides-treatment-pdq">Chemotherapy</SummaryRef>.</ListItem><ListItem><SummaryRef href="CDR0000062881#_672" url="/types/lymphoma/hp/mycosis-fungoides-treatment-pdq">Other drug therapy</SummaryRef>.</ListItem><ListItem><SummaryRef href="CDR0000062881#_674" url="/types/lymphoma/hp/mycosis-fungoides-treatment-pdq">Biological therapy</SummaryRef>.</ListItem><ListItem><SummaryRef href="CDR0000062881#_676" url="/types/lymphoma/hp/mycosis-fungoides-treatment-pdq">Allogeneic stem cell transplant</SummaryRef>.</ListItem><ListItem><SummaryRef href="CDR0000062881#_678" url="/types/lymphoma/hp/mycosis-fungoides-treatment-pdq">Targeted therapy</SummaryRef>.</ListItem></OrderedList><SummarySection id="_666"><Title>Radiation therapy</Title><OrderedList id="_667" Style="Arabic"><ListItem>Additional electron-beam radiation therapy or a repeat of TSEB.<ItemizedList id="_687" Style="bullet"><ListItem>Electron-beam radiation therapy of
appropriate energies will penetrate only to the dermis, and thus, the skin alone
can be treated without systemic effects.  This therapy requires a
radiation therapy facility with physics support and considerable
technical expertise to deliver precise dosimetry. TSEB can result in short- and long-term cutaneous
toxic effects and is not widely available.  </ListItem><ListItem>This therapy can provide excellent palliation, with
complete response rates as high as  80%, and may be combined with systemic treatment. Based on the long-term survival of
these early-stage patients, electron-beam radiation therapy is sometimes used with 
curative intent.<Reference refidx="4"/><Reference refidx="5"/><Reference refidx="6"/><Reference refidx="7"/><Reference refidx="8"/>  Long-term disease-free survival (DFS) can be achieved in
patients with unilesional mycosis fungoides treated with local radiation
therapy.<Reference refidx="9"/></ListItem></ItemizedList></ListItem><ListItem>Photon radiation to bulky skin or nodal masses.<Reference refidx="10"/></ListItem></OrderedList></SummarySection><SummarySection id="_668"><Title>Photodynamic therapy</Title><OrderedList id="_669" Style="Arabic"><ListItem>PUVA radiation therapy.<Reference refidx="11"/><Reference refidx="12"/><Reference refidx="13"/><Reference refidx="14"/><Reference refidx="15"/><Reference refidx="16"/><ItemizedList id="_688" Style="bullet"><ListItem>Therapeutic trials with PUVA
have shown an 80% to 90% complete remission rate in patients, with those in early cutaneous stages
achieving the best responses.  PUVA may be used in conjunction with systemic
treatment.<Reference refidx="15"/>  Continued maintenance therapy with PUVA at more
protracted intervals is generally required to prolong remission duration.<Reference refidx="11"/><Reference refidx="12"/><Reference refidx="13"/><Reference refidx="15"/> 
PUVA combined with interferon alfa-2a is associated with a high response 
rate.<Reference refidx="14"/><Reference refidx="15"/></ListItem></ItemizedList></ListItem><ListItem>Narrowband ultraviolet B radiation.<Reference refidx="17"/><Reference refidx="18"/><ItemizedList id="_689" Style="bullet"><ListItem>Single-arm and retrospective comparisons confirm the efficacy of narrowband ultraviolet B with 80% to 90% complete remission rates, especially for patients with early cutaneous stages.<Reference refidx="17"/><Reference refidx="18"/></ListItem><ListItem>A Cochrane systematic review and meta-analysis compared PUVA with narrowband ultraviolet B radiation in 778 patients with early-stage mycosis fungoides (stage IA, IB, and IIA). Significantly higher complete response rates were seen in patients treated with PUVA (73.8% vs. 62.2%; hazard ratio [HR], 1.68; 95% confidence interval [CI], 1.02–2.76; <Emphasis>P</Emphasis> = .04). There were  no significant differences in adverse effects.<Reference refidx="16"/>[<LOERef href="CDR0000810031" dictionary="NotSet" audience="Health professional">Level of evidence B3</LOERef>]</ListItem></ItemizedList></ListItem><ListItem>Extracorporeal photophoresis (ECP) has produced tumor
regression in patients who are resistant to other therapies.<Reference refidx="19"/><Reference refidx="20"/><ItemizedList id="_690" Style="bullet"><ListItem>In a retrospective analysis of 65 patients, with a median follow-up of 48 months, use of ECP in the first to third line of treatment yielded a longer median time-to-next treatment (TTNT) than other systemic options (<Emphasis>P</Emphasis> &lt; .03).<Reference refidx="21"/>[<LOERef href="CDR0000810039" dictionary="NotSet" audience="Health professional">Level of evidence C3</LOERef>]</ListItem></ItemizedList></ListItem></OrderedList></SummarySection><SummarySection id="_670"><Title>Chemotherapy</Title><OrderedList id="_671" Style="Arabic"><ListItem>Topical treatment with mechlorethamine or PUVA.<ItemizedList id="_691" Style="bullet"><ListItem>This form of treatment may be
used palliatively or to supplement therapeutic approaches directed against
nodal or visceral disease.  Topical application of
mechlorethamine has produced regression of cutaneous lesions, with particular
efficacy in early stages of disease.  The overall complete remission rate is
related to skin stage; 50% to 80% of TNM classification T1 patients, 25% to 75% of
T2 patients, as many as  50% of T3
patients, and 20% to 40% of T4 patients  have complete responses.  The overall complete remission rate in 243 patients
was 64% and was related to stage; as many as 35% of stage IV patients had complete
responses. Treatments are usually continued for 2 to
3 years.  Continuous 5-year DFS may be possible in  as many as 33% of T1 patients.<Reference refidx="4"/><Reference refidx="22"/><Reference refidx="23"/></ListItem></ItemizedList></ListItem><ListItem>Pralatrexate (folate analogue).<Reference refidx="24"/><Reference refidx="25"/><ItemizedList id="_692" Style="bullet"><ListItem>Chemotherapeutic agents generally yield short durations of response. In a retrospective review of 198 patients with advanced-stage disease, the median TTNT was 4 months.<Reference refidx="26"/></ListItem></ItemizedList></ListItem><ListItem>Pegylated liposomal doxorubicin.<Reference refidx="27"/><Reference refidx="28"/><Reference refidx="29"/></ListItem><ListItem>Systemic chemotherapy: chlorambucil plus prednisone, mechlorethamine,
cyclophosphamide, methotrexate, and combination chemotherapy.<Reference refidx="26"/><Reference refidx="30"/><Reference refidx="31"/><Reference refidx="32"/></ListItem></OrderedList></SummarySection><SummarySection id="_672"><Title>Other drug therapy</Title><OrderedList id="_673" Style="Arabic"><ListItem>Symptomatic management with topical corticosteroids.</ListItem><ListItem>Bexarotene, an oral or topical retinoid.<Reference refidx="33"/><Reference refidx="34"/></ListItem><ListItem>Lenalidomide.<Reference refidx="35"/></ListItem><ListItem>Vorinostat or romidepsin or other histone deacetylase inhibitors (HDACi).<Reference refidx="36"/><Reference refidx="37"/><Reference refidx="38"/><ItemizedList id="_700" Style="bullet"><ListItem>A retrospective review of 198 patients with mycosis fungoides and Sézary syndrome compared the TTNT between HDACi and conventional chemotherapy. HDACi provided a longer TTNT of 4.5 months (95% CI, 4.0–6.1) than did chemotherapy, with a TTNT of 3.9 months (95% CI, 3.2–5.1; <Emphasis>P</Emphasis> = .01).<Reference refidx="26"/>[<LOERef href="CDR0000810039" dictionary="NotSet" audience="Health professional">Level of evidence C3</LOERef>]</ListItem></ItemizedList></ListItem></OrderedList></SummarySection><SummarySection id="_674"><Title>Biological therapy</Title><OrderedList id="_675" Style="Arabic"><ListItem>Interferon alfa alone or in combination with other agents, such as topical therapy.<Reference refidx="39"/><Reference refidx="40"/><ItemizedList id="_693" Style="bullet"><ListItem>A retrospective review of 198 patients with mycosis fungoides and Sézary syndrome compared the TTNT between patients who received interferon alfa and conventional chemotherapy. Interferon alfa provided a longer TTNT of 8.7 months (95% CI, 6.0–18.0) than did chemotherapy, with a TTNT of 3.9 months (95% CI, 3.2–5.1) (<Emphasis>P</Emphasis> &lt; .00001).<Reference refidx="26"/>[<LOERef href="CDR0000810039" dictionary="NotSet" audience="Health professional">Level of evidence C3</LOERef>]</ListItem></ItemizedList></ListItem></OrderedList></SummarySection><SummarySection id="_676"><Title>Allogeneic stem cell transplant</Title><OrderedList id="_677" Style="Arabic"><ListItem>Allogeneic stem cell transplant (SCT).<Reference refidx="41"/><Reference refidx="42"/><Reference refidx="43"/><Reference refidx="43"/><Reference refidx="44"/><Reference refidx="45"/><ItemizedList id="_694" Style="bullet"><ListItem>Among highly selected patients, the 5-year overall survival (OS) rate ranges from 30% to 50%, with a relapse-free survival rate of 15% to 25%.<Reference refidx="41"/><Reference refidx="42"/><Reference refidx="43"/><Reference refidx="44"/><Reference refidx="45"/></ListItem></ItemizedList></ListItem></OrderedList></SummarySection><SummarySection id="_678"><Title>Targeted therapy</Title><OrderedList id="_679" Style="Arabic"><ListItem>Brentuximab vedotin.<Reference refidx="46"/><Reference refidx="47"/><ItemizedList id="_695" Style="bullet"><ListItem>Two phase II trials of 58 patients with variable CD30 expression showed a 50% to 70% response rate with 50% of patients still in remission after 1 year.<Reference refidx="46"/><Reference refidx="47"/>[<LOERef href="CDR0000810039" dictionary="NotSet" audience="Health professional">Level of evidence C3</LOERef>] </ListItem></ItemizedList></ListItem><ListItem>Mogamulizumab.<Reference refidx="48"/><OrderedList id="_696" Style="LAlpha"><ListItem>In a prospective randomized trial, 372 previously treated patients received either mogamulizumab, a monoclonal antibody directed against C-C chemokine receptor 4, or the HDACi vorinostat. <ItemizedList id="_697" Style="bullet"><ListItem>With a median follow-up of 17 months, the median progression-free survival was 7.7 months for patients who received mogamulizumab and 3.1 months for patients who received vorinostat (HR, 0.53; 95% CI, 0.41−0.69; <Emphasis>P</Emphasis> &lt; .0001).<Reference refidx="48"/>[<LOERef href="CDR0000810025" dictionary="NotSet" audience="Health professional">Level of evidence B1</LOERef>]</ListItem><ListItem> Mogamulizumab appeared to be especially effective in patients with blood involvement, such as those with Sézary syndrome.</ListItem><ListItem>This preliminary study was not designed to detect differences in OS.</ListItem></ItemizedList></ListItem></OrderedList><Para id="_715">Mogamulizumab is often avoided in patients scheduled to undergo allogeneic SCT, based on data from a Japanese study that showed an increased risk of severe graft-versus-host disease (GVHD) in patients treated with mogamulizumab beforehand.<Reference refidx="49"/> The relevance of these findings in other countries and the impact of different GVHD prophylaxis regimens in these patients remains to be determined.</Para></ListItem></OrderedList></SummarySection></SummarySection><SummarySection id="_TrialSearch_102_sid_7"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_102_22">Use our <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials-search/advanced">advanced clinical trial search</ExternalRef> to find NCI-supported cancer clinical trials that are now enrolling patients. The search can be narrowed by location of the trial, type of treatment, name of the drug, and other criteria. <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials">General information</ExternalRef> about clinical trials is also available.</Para></SummarySection><ReferenceSection><Citation idx="1" PMID="7635786" MedlineID="95362609">Becker M, Hoppe RT, Knox SJ: Multiple courses of high-dose total skin electron beam therapy in the management of mycosis fungoides. Int J Radiat Oncol Biol Phys 32 (5): 1445-9, 1995.</Citation><Citation idx="2" PMID="16574401">Trautinger F, Knobler R, Willemze R, et al.: EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome. Eur J Cancer 42 (8): 1014-30, 2006.</Citation><Citation idx="3" PMID="20212249">Prince HM, Duvic M, Martin A, et al.: Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma. J Clin Oncol 28 (11): 1870-7, 2010.</Citation><Citation idx="4" PMID="10192339" MedlineID="99206557">Chinn DM, Chow S, Kim YH, et al.: Total skin electron beam therapy with or without adjuvant topical nitrogen mustard or nitrogen mustard alone as initial treatment of T2 and T3 mycosis fungoides. Int J Radiat Oncol Biol Phys 43 (5): 951-8, 1999.</Citation><Citation idx="5" PMID="9276369" MedlineID="97420384">Quirós PA, Jones GW, Kacinski BM, et al.: Total skin electron beam therapy followed by adjuvant psoralen/ultraviolet-A light in the management of patients with T1 and T2 cutaneous T-cell lymphoma (mycosis fungoides). Int J Radiat Oncol Biol Phys 38 (5): 1027-35, 1997.</Citation><Citation idx="6" PMID="15001254">Ysebaert L, Truc G, Dalac S, et al.: Ultimate results of radiation therapy for T1-T2 mycosis fungoides (including reirradiation). Int J Radiat Oncol Biol Phys 58 (4): 1128-34, 2004.</Citation><Citation idx="7" PMID="10223240" MedlineID="99237751">Jones GW, Rosenthal D, Wilson LD: Total skin electron radiation for patients with erythrodermic cutaneous T-cell lymphoma (mycosis fungoides and the Sézary syndrome). Cancer 85 (9): 1985-95, 1999.</Citation><Citation idx="8" PMID="21576575">Navi D, Riaz N, Levin YS, et al.: The Stanford University experience with conventional-dose, total skin electron-beam therapy in the treatment of generalized patch or plaque (T2) and tumor (T3) mycosis fungoides. Arch Dermatol 147 (5): 561-7, 2011.</Citation><Citation idx="9" PMID="9788416" MedlineID="99002465">Micaily B, Miyamoto C, Kantor G, et al.: Radiotherapy for unilesional mycosis fungoides. Int J Radiat Oncol Biol Phys 42 (2): 361-4, 1998.</Citation><Citation idx="10" PMID="22818412">Thomas TO, Agrawal P, Guitart J, et al.: Outcome of patients treated with a single-fraction dose of palliative radiation for cutaneous T-cell lymphoma. Int J Radiat Oncol Biol Phys 85 (3): 747-53, 2013.</Citation><Citation idx="11" PMID="7622650" MedlineID="95348292">Herrmann JJ, Roenigk HH, Hurria A, et al.: Treatment of mycosis fungoides with photochemotherapy (PUVA): long-term follow-up. J Am Acad Dermatol 33 (2 Pt 1): 234-42, 1995.</Citation><Citation idx="12" PMID="1626959" MedlineID="92328537">Ramsay DL, Lish KM, Yalowitz CB, et al.: Ultraviolet-B phototherapy for early-stage cutaneous T-cell lymphoma. Arch Dermatol 128 (7): 931-3, 1992.</Citation><Citation idx="13" PMID="15781671">Querfeld C, Rosen ST, Kuzel TM, et al.: Long-term follow-up of patients with early-stage cutaneous T-cell lymphoma who achieved complete remission with psoralen plus UV-A monotherapy. Arch Dermatol 141 (3): 305-11, 2005.</Citation><Citation idx="14" PMID="7799028" MedlineID="95096954">Kuzel TM, Roenigk HH, Samuelson E, et al.: Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fungoides and the Sézary syndrome. J Clin Oncol 13 (1): 257-63, 1995.</Citation><Citation idx="15" PMID="26547257">Olsen EA, Hodak E, Anderson T, et al.: Guidelines for phototherapy of mycosis fungoides and Sézary syndrome: A consensus statement of the United States Cutaneous Lymphoma Consortium. J Am Acad Dermatol 74 (1): 27-58, 2016.</Citation><Citation idx="16" PMID="30698622">Phan K, Ramachandran V, Fassihi H, et al.: Comparison of Narrowband UV-B With Psoralen-UV-A Phototherapy for Patients With Early-Stage Mycosis Fungoides: A Systematic Review and Meta-analysis. JAMA Dermatol 155 (3): 335-341, 2019.</Citation><Citation idx="17" PMID="28711574">Almohideb M, Walsh S, Walsh S, et al.: Bath Psoralen-ultraviolet A and Narrowband Ultraviolet B Phototherapy as Initial Therapy for Early-stage Mycosis Fungoides: A Retrospective Cohort of 267 Cases at the University of Toronto. Clin Lymphoma Myeloma Leuk 17 (9): 604-612, 2017.</Citation><Citation idx="18" PMID="23030414">Elcin G, Duman N, Karahan S, et al.: Long-term follow-up of early mycosis fungoides patients treated with narrowband ultraviolet B phototherapy. J Dermatolog Treat 25 (3): 268-73, 2014.</Citation><Citation idx="19" PMID="3543674" MedlineID="87115645">Edelson R, Berger C, Gasparro F, et al.: Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results. N Engl J Med 316 (6): 297-303, 1987.</Citation><Citation idx="20" PMID="2191335" MedlineID="90280574">Heald PW, Perez MI, McKiernan G, et al.: Extracorporeal photochemotherapy for CTCL. Prog Clin Biol Res 337: 443-7, 1990.</Citation><Citation idx="21" PMID="31467061">Gao C, McCormack C, van der Weyden C, et al.: Prolonged survival with the early use of a novel extracorporeal photopheresis regimen in patients with Sézary syndrome. Blood 134 (16): 1346-1350, 2019.</Citation><Citation idx="22" PMID="23069814">Lessin SR, Duvic M, Guitart J, et al.: Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. JAMA Dermatol 149 (1): 25-32, 2013.</Citation><Citation idx="23" PMID="16172308">de Quatrebarbes J, Estève E, Bagot M, et al.: Treatment of early-stage mycosis fungoides with twice-weekly applications of mechlorethamine and topical corticosteroids: a prospective study. Arch Dermatol 141 (9): 1117-20, 2005.</Citation><Citation idx="24" PMID="22394596">Horwitz SM, Kim YH, Foss F, et al.: Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood 119 (18): 4115-22, 2012.</Citation><Citation idx="25" PMID="24589156">Talpur R, Thompson A, Gangar P, et al.: Pralatrexate alone or in combination with bexarotene: long-term tolerability in relapsed/refractory mycosis fungoides. Clin Lymphoma Myeloma Leuk 14 (4): 297-304, 2014.</Citation><Citation idx="26" PMID="25336628">Hughes CF, Khot A, McCormack C, et al.: Lack of durable disease control with chemotherapy for mycosis fungoides and Sézary syndrome: a comparative study of systemic therapy. Blood 125 (1): 71-81, 2015.</Citation><Citation idx="27" PMID="23045580">Dummer R, Quaglino P, Becker JC, et al.: Prospective international multicenter phase II trial of intravenous pegylated liposomal doxorubicin monochemotherapy in patients with stage IIB, IVA, or IVB advanced mycosis fungoides: final results from EORTC 21012. J Clin Oncol 30 (33): 4091-7, 2012.</Citation><Citation idx="28" PMID="12942567">Wollina U, Dummer R, Brockmeyer NH, et al.: Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma. Cancer 98 (5): 993-1001, 2003.</Citation><Citation idx="29" PMID="18559761">Quereux G, Marques S, Nguyen JM, et al.: Prospective multicenter study of pegylated liposomal doxorubicin treatment in patients with advanced or refractory mycosis fungoides or Sézary syndrome. Arch Dermatol 144 (6): 727-33, 2008.</Citation><Citation idx="30" PMID="2594037" MedlineID="90081777">Kaye FJ, Bunn PA, Steinberg SM, et al.: A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med 321 (26): 1784-90, 1989.</Citation><Citation idx="31" PMID="8522487" MedlineID="96087569">Rosen ST, Foss FM: Chemotherapy for mycosis fungoides and the Sézary syndrome. Hematol Oncol Clin North Am 9 (5): 1109-16, 1995.</Citation><Citation idx="32" PMID="2808792" MedlineID="90037735">Zackheim HS, Epstein EH: Low-dose methotrexate for the Sézary syndrome. J Am Acad Dermatol 21 (4 Pt 1): 757-62, 1989.</Citation><Citation idx="33" PMID="9053506" MedlineID="97178773">Miller VA, Benedetti FM, Rigas JR, et al.: Initial clinical trial of a selective retinoid X receptor ligand, LGD1069. J Clin Oncol 15 (2): 790-5, 1997.</Citation><Citation idx="34" PMID="11331325" MedlineID="21229775">Duvic M, Hymes K, Heald P, et al.: Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol 19 (9): 2456-71, 2001.</Citation><Citation idx="35" PMID="24335103">Querfeld C, Rosen ST, Guitart J, et al.: Results of an open-label multicenter phase 2 trial of lenalidomide monotherapy in refractory mycosis fungoides and Sézary syndrome. Blood 123 (8): 1159-66, 2014.</Citation><Citation idx="36" PMID="22981498">Duvic M, Dummer R, Becker JC, et al.: Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: results of a phase II trial. Eur J Cancer 49 (2): 386-94, 2013.</Citation><Citation idx="37" PMID="17577020">Olsen EA, Kim YH, Kuzel TM, et al.: Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 25 (21): 3109-15, 2007.</Citation><Citation idx="38" PMID="19826128">Piekarz RL, Frye R, Turner M, et al.: Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 27 (32): 5410-7, 2009.</Citation><Citation idx="39" PMID="1453206" MedlineID="93085392">Foss FM, Ihde DC, Breneman DL, et al.: Phase II study of pentostatin and intermittent high-dose recombinant interferon alfa-2a in advanced mycosis fungoides/Sézary syndrome. J Clin Oncol 10 (12): 1907-13, 1992.</Citation><Citation idx="40" PMID="8522486" MedlineID="96087568">Olsen EA, Bunn PA: Interferon in the treatment of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 9 (5): 1089-107, 1995.</Citation><Citation idx="41" PMID="16135483">Molina A, Zain J, Arber DA, et al.: Durable clinical, cytogenetic, and molecular remissions after allogeneic hematopoietic cell transplantation for refractory Sezary syndrome and mycosis fungoides. J Clin Oncol 23 (25): 6163-71, 2005.</Citation><Citation idx="42" PMID="20351328">Duvic M, Donato M, Dabaja B, et al.: Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sezary syndrome. J Clin Oncol 28 (14): 2365-72, 2010.</Citation><Citation idx="43" PMID="25154828">Duarte RF, Boumendil A, Onida F, et al.: Long-term outcome of allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a European society for blood and marrow transplantation lymphoma working party extended analysis. J Clin Oncol 32 (29): 3347-8, 2014.</Citation><Citation idx="44" PMID="22258991">Schlaak M, Pickenhain J, Theurich S, et al.: Allogeneic stem cell transplantation versus conventional therapy for advanced primary cutaneous T-cell lymphoma. Cochrane Database Syst Rev 1: CD008908, 2012.</Citation><Citation idx="45" PMID="25068422">Lechowicz MJ, Lazarus HM, Carreras J, et al.: Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndrome. Bone Marrow Transplant 49 (11): 1360-5, 2014.</Citation><Citation idx="46" PMID="26195720">Kim YH, Tavallaee M, Sundram U, et al.: Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project. J Clin Oncol 33 (32): 3750-8, 2015.</Citation><Citation idx="47" PMID="26261247">Duvic M, Tetzlaff MT, Gangar P, et al.: Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis. J Clin Oncol 33 (32): 3759-65, 2015.</Citation><Citation idx="48" PMID="30100375">Kim YH, Bagot M, Pinter-Brown L, et al.: Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol 19 (9): 1192-1204, 2018.</Citation><Citation idx="49" PMID="27220263">Sugio T, Kato K, Aoki T, et al.: Mogamulizumab Treatment Prior to Allogeneic Hematopoietic Stem Cell Transplantation Induces Severe Acute Graft-versus-Host Disease. Biol Blood Marrow Transplant 22 (9): 1608-1614, 2016.</Citation></ReferenceSection></SummarySection><SummarySection id="_613"><SectMetaData><SpecificDiagnosis ref="CDR0000042785">anaplastic large cell lymphoma</SpecificDiagnosis><SpecificDiagnosis ref="CDR0000043725">cutaneous T-cell non-Hodgkin lymphoma</SpecificDiagnosis><SectionType>Treatment options by stage</SectionType></SectMetaData><Title>Treatment of Primary Cutaneous Anaplastic Large Cell Lymphoma</Title><Para id="_614">Primary cutaneous anaplastic large cell lymphoma presents in the skin only with no preexisting lymphoproliferative disease and no extracutaneous sites of involvement.<Reference refidx="1"/><Reference refidx="2"/><Reference refidx="3"/> Patients with this type of lymphoma have disease ranging from clinically benign lymphomatoid papulosis, marked by localized nodules that may regress spontaneously, to progressive and systemic illness requiring aggressive doxorubicin-based combination chemotherapy. This spectrum has been called the primary cutaneous CD30-positive T-cell lymphoproliferative disorder.</Para><Para id="_615">Patients with localized disease usually undergo radiation therapy. With more disseminated involvement, watchful waiting or doxorubicin-based combination chemotherapy is used.<Reference refidx="1"/><Reference refidx="2"/><Reference refidx="3"/></Para><SummarySection id="_TrialSearch_613_sid_8"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_613_22">Use our <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials-search/advanced">advanced clinical trial search</ExternalRef> to find NCI-supported cancer clinical trials that are now enrolling patients. The search can be narrowed by location of the trial, type of treatment, name of the drug, and other criteria. <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials">General information</ExternalRef> about clinical trials is also available.</Para></SummarySection><ReferenceSection><Citation idx="1" PMID="8406384" MedlineID="94010779">de Bruin PC, Beljaards RC, van Heerde P, et al.: Differences in clinical behaviour and immunophenotype between primary cutaneous and primary nodal anaplastic large cell lymphoma of T-cell or null cell phenotype. Histopathology 23 (2): 127-35, 1993.</Citation><Citation idx="2" PMID="8388410" MedlineID="93266940">Willemze R, Beljaards RC: Spectrum of primary cutaneous CD30 (Ki-1)-positive lymphoproliferative disorders. A proposal for classification and guidelines for management and treatment. J Am Acad Dermatol 28 (6): 973-80, 1993.</Citation><Citation idx="3" PMID="21841159">Kempf W, Pfaltz K, Vermeer MH, et al.: EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood 118 (15): 4024-35, 2011.</Citation></ReferenceSection></SummarySection><SummarySection id="_617"><SectMetaData><SpecificDiagnosis ref="CDR0000043725">cutaneous T-cell non-Hodgkin lymphoma</SpecificDiagnosis><SectionType>Treatment options by stage</SectionType></SectMetaData><Title>Treatment of Subcutaneous Panniculitis-Like T-Cell Lymphoma</Title><Para id="_618">Subcutaneous panniculitis-like T-cell lymphoma  (SPTCL) is localized to subcutaneous tissue and can be associated with hemophagocytic lymphohistiocytosis (HLH).<Reference refidx="1"/><Reference refidx="2"/><Reference refidx="3"/><Reference refidx="4"/> Anecdotal reports suggest that the presence or absence of HLH is an important prognostic indicator.<Reference refidx="5"/> Patients with SPTCL  have cells that express alpha-beta phenotype. </Para><Para id="_701">Patients with gamma-delta phenotype have a more aggressive clinical course that is instead classified as primary cutaneous gamma-delta T-cell lymphoma.<Reference refidx="6"/><Reference refidx="7"/><Reference refidx="8"/> For more information, see <SummaryRef href="CDR0000811763" url="/types/lymphoma/hp/peripheral-t-cell-lymphoma-pdq">Peripheral T-Cell Non-Hodgkin Lymphoma Treatment</SummaryRef>.</Para><Para id="_716">The management of SPTCL depends on the clinical presentation—including the severity of symptoms, cytopenias, and the presence or absence of HLH—and the apparent disease trajectory and aggressiveness. Indolent or smoldering forms of SPTCL are often treated with immunosuppression, including oral methotrexate <Reference refidx="9"/> or cyclosporine.<Reference refidx="10"/> In contrast, aggressive forms are frequently treated with combination chemotherapy such as CHO(E)P (cyclophosphamide, doxorubicin, vincristine, and prednisone with or without etoposide) with variable responses per anecdotal reports.<Reference refidx="11"/> The JAK2 inhibitor ruxolitinib has also been used in SPTCL with associated HLH, including anecdotal reports of responses in patients with disease that did not respond to CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) therapy.<Reference refidx="12"/>  In cases of particularly aggressive or relapsed disease, consolidation with allogeneic stem cell transplant has also been used.<Reference refidx="13"/><Reference refidx="14"/></Para><SummarySection id="_TrialSearch_617_sid_9"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_617_22">Use our <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials-search/advanced">advanced clinical trial search</ExternalRef> to find NCI-supported cancer clinical trials that are now enrolling patients. The search can be narrowed by location of the trial, type of treatment, name of the drug, and other criteria. <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials">General information</ExternalRef> about clinical trials is also available.</Para></SummarySection><ReferenceSection><Citation idx="1" PMID="15368328">Go RS, Wester SM: Immunophenotypic and molecular features, clinical outcomes, treatments, and prognostic factors associated with subcutaneous panniculitis-like T-cell lymphoma: a systematic analysis of 156 patients reported in the literature. Cancer 101 (6): 1404-13, 2004.</Citation><Citation idx="2" PMID="10890991">Marzano AV, Berti E, Paulli M, et al.: Cytophagic histiocytic panniculitis and subcutaneous panniculitis-like T-cell lymphoma: report of 7 cases. Arch Dermatol 136 (7): 889-96, 2000.</Citation><Citation idx="3" PMID="12653744">Hoque SR, Child FJ, Whittaker SJ, et al.: Subcutaneous panniculitis-like T-cell lymphoma: a clinicopathological, immunophenotypic and molecular analysis of six patients. Br J Dermatol 148 (3): 516-25, 2003.</Citation><Citation idx="4" PMID="9669350" MedlineID="98332013">Salhany KE, Macon WR, Choi JK, et al.: Subcutaneous panniculitis-like T-cell lymphoma: clinicopathologic, immunophenotypic, and genotypic analysis of alpha/beta and gamma/delta subtypes. Am J Surg Pathol 22 (7): 881-93, 1998.</Citation><Citation idx="5" PMID="27986433">Willemze R: Cutaneous lymphomas with a panniculitic presentation. Semin Diagn Pathol 34 (1): 36-43, 2017.</Citation><Citation idx="6" PMID="15166664">Massone C, Chott A, Metze D, et al.: Subcutaneous, blastic natural killer (NK), NK/T-cell, and other cytotoxic lymphomas of the skin: a morphologic, immunophenotypic, and molecular study of 50 patients. Am J Surg Pathol 28 (6): 719-35, 2004.</Citation><Citation idx="7" PMID="9473239">Arnulf B, Copie-Bergman C, Delfau-Larue MH, et al.: Nonhepatosplenic gammadelta T-cell lymphoma: a subset of cytotoxic lymphomas with mucosal or skin localization. Blood 91 (5): 1723-31, 1998.</Citation><Citation idx="8" PMID="12522013">Toro JR, Liewehr DJ, Pabby N, et al.: Gamma-delta T-cell phenotype is associated with significantly decreased survival in cutaneous T-cell lymphoma. Blood 101 (9): 3407-12, 2003.</Citation><Citation idx="9" PMID="30677832">Grinich E, Koon SM, Cascio MJ, et al.: Subcutaneous panniculitis-like T-cell lymphoma responsive to combination therapy with methotrexate and corticosteroids. Dermatol Online J 24 (9): , 2018.</Citation><Citation idx="10" PMID="17454599">Rojnuckarin P, Nakorn TN, Assanasen T, et al.: Cyclosporin in subcutaneous panniculitis-like T-cell lymphoma. Leuk Lymphoma 48 (3): 560-3, 2007.</Citation><Citation idx="11" PMID="17934071">Willemze R, Jansen PM, Cerroni L, et al.: Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases. Blood 111 (2): 838-45, 2008.</Citation><Citation idx="12" PMID="32271897">Lévy R, Fusaro M, Guerin F, et al.: Efficacy of ruxolitinib in subcutaneous panniculitis-like T-cell lymphoma and hemophagocytic lymphohistiocytosis. Blood Adv 4 (7): 1383-1387, 2020.</Citation><Citation idx="13">Weng W, Iragavarapu C, Weng GM, et al.: Long-term remission with allogeneic transplant in patients with refractory/relapsed cutaneous cytotoxic T-cell lymphoma. Blood Neoplasia  1 (2): 2024.</Citation><Citation idx="14" PMID="17071503">Ichii M, Hatanaka K, Imakita M, et al.: Successful treatment of refractory subcutaneous panniculitis-like T-cell lymphoma with allogeneic peripheral blood stem cell transplantation from HLA-mismatched sibling donor. Leuk Lymphoma 47 (10): 2250-2, 2006.</Citation></ReferenceSection></SummarySection><SummarySection id="_717"><SectMetaData><SpecificDiagnosis ref="CDR0000043725">cutaneous T-cell non-Hodgkin lymphoma</SpecificDiagnosis><SectionType>Treatment options by stage</SectionType></SectMetaData><Title>Treatment of Primary Cutaneous Gamma-Delta T-Cell Lymphoma</Title><Para id="_718">Primary cutaneous gamma-delta T-cell lymphoma (PCGDTCL) is a rare and extremely aggressive form of cutaneous T-cell lymphoma with a poor prognosis. These patients may manifest involvement of the epidermis, dermis, subcutaneous region, or mucosa with or without ulceration. PCGDTCL is treated similarly to the most aggressive peripheral T-cell lymphomas, with CHO(E)P (cyclophosphamide doxorubicin, vincristine, and prednisone with or without etoposide).<Reference refidx="1"/><Reference refidx="2"/><Reference refidx="3"/><Reference refidx="4"/><Reference refidx="5"/>  For patients achieving remission, there are reports of prolonged survival following consolidation with allogeneic stem cell transplant.<Reference refidx="6"/>  </Para><SummarySection id="_TrialSearch_717_sid_10"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_717_22">Use our <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials-search/advanced">advanced clinical trial search</ExternalRef> to find NCI-supported cancer clinical trials that are now enrolling patients. The search can be narrowed by location of the trial, type of treatment, name of the drug, and other criteria. <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials">General information</ExternalRef> about clinical trials is also available.</Para></SummarySection><ReferenceSection><Citation idx="1" PMID="9473239">Arnulf B, Copie-Bergman C, Delfau-Larue MH, et al.: Nonhepatosplenic gammadelta T-cell lymphoma: a subset of cytotoxic lymphomas with mucosal or skin localization. Blood 91 (5): 1723-31, 1998.</Citation><Citation idx="2" PMID="12522013">Toro JR, Liewehr DJ, Pabby N, et al.: Gamma-delta T-cell phenotype is associated with significantly decreased survival in cutaneous T-cell lymphoma. Blood 101 (9): 3407-12, 2003.</Citation><Citation idx="3" PMID="18390969">Le Gouill S, Milpied N, Buzyn A, et al.: Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Société Francaise de Greffe de Moëlle et de Thérapie Cellulaire. J Clin Oncol 26 (14): 2264-71, 2008.</Citation><Citation idx="4" PMID="32756940">Pro B, Allen P, Behdad A: Hepatosplenic T-cell lymphoma: a rare but challenging entity. Blood 136 (18): 2018-2026, 2020.</Citation><Citation idx="5" PMID="34842638">Alberti-Violetti S, Maronese CA, Venegoni L, et al.: Primary Cutaneous Gamma-Delta T Cell Lymphomas: A Case Series and Overview of the Literature. Dermatopathology (Basel) 8 (4): 515-524, 2021.</Citation><Citation idx="6" PMID="32643494">Isufi I, Seropian S, Gowda L, et al.: Outcomes for allogeneic stem cell transplantation in refractory mycosis fungoides and primary cutaneous gamma Delta T cell lymphomas. Leuk Lymphoma 61 (12): 2955-2961, 2020.</Citation></ReferenceSection></SummarySection><SummarySection id="_719"><SectMetaData><SpecificDiagnosis ref="CDR0000043725">cutaneous T-cell non-Hodgkin lymphoma</SpecificDiagnosis><SectionType>Treatment options by stage</SectionType></SectMetaData><Title>Treatment of Primary Cutaneous Aggressive Epidermotropic CD8-Positive T-Cell Lymphoma</Title><Para id="_720">Primary cutaneous aggressive epidermotropic CD8-positive T-cell lymphoma is another rare and especially aggressive form of cutaneous T-cell lymphoma. Patients typically present with ulcerative plaques or tumors, and mucosal involvement is common. Neoplastic cells are characterized by expression of CD8 and a cytotoxic phenotype.<Reference refidx="1"/> Multimodal chemotherapy, such as CHO(E)P (cyclophosphamide, doxorubicin, vincristine, and prednisone with or without etoposide), is often used. Outcomes are generally poor, and prolonged remissions are extremely uncommon in the absence of allogeneic stem cell transplant.<Reference refidx="2"/>  </Para><SummarySection id="_TrialSearch_719_sid_11"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_719_22">Use our <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials-search/advanced">advanced clinical trial search</ExternalRef> to find NCI-supported cancer clinical trials that are now enrolling patients. The search can be narrowed by location of the trial, type of treatment, name of the drug, and other criteria. <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials">General information</ExternalRef> about clinical trials is also available.</Para></SummarySection><ReferenceSection><Citation idx="1" PMID="22226429">Nofal A, Abdel-Mawla MY, Assaf M, et al.: Primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma: proposed diagnostic criteria and therapeutic evaluation. J Am Acad Dermatol 67 (4): 748-59, 2012.</Citation><Citation idx="2" PMID="28128277">Guitart J, Martinez-Escala ME, Subtil A, et al.: Primary cutaneous aggressive epidermotropic cytotoxic T-cell lymphomas: reappraisal of a provisional entity in the 2016 WHO classification of cutaneous lymphomas. Mod Pathol 30 (5): 761-772, 2017.</Citation></ReferenceSection></SummarySection><SummarySection id="_329"><Title>Key References for Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas</Title><Para id="_333">These references have been identified by members of the <ExternalRef xref="https://www.cancer.gov/publications/pdq/editorial-boards/adult-treatment">PDQ Adult Treatment Editorial Board</ExternalRef> as significant in the field of mycosis fungoides and other cutaneous T-cell lymphoma   treatment.  This list is provided to inform users of important studies that have helped shape the current understanding of and treatment options for MF/SS. Listed after each reference are the sections within this summary where the reference is cited.</Para><ItemizedList id="_330" Style="bullet"><ListItem>Agar NS, Wedgeworth E, Crichton S, et al.: Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol 28 (31): 4730-9, 2010. [<ExternalRef xref="https://www.ncbi.nlm.nih.gov/pubmed/?term=20855822">PUBMED Abstract</ExternalRef>]<Para id="_344">Cited in:</Para><ItemizedList id="_339" Style="bullet"><ListItem><SummaryRef href="CDR0000062881#_1" url="/types/lymphoma/hp/mycosis-fungoides-treatment-pdq">General Information About Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas</SummaryRef></ListItem><ListItem><SummaryRef href="CDR0000062881#_10" url="/types/lymphoma/hp/mycosis-fungoides-treatment-pdq">Stage Information for Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas</SummaryRef></ListItem></ItemizedList></ListItem><ListItem>Hughes CF, Khot A, McCormack C, et al.: Lack of durable disease control with chemotherapy for mycosis fungoides and Sézary syndrome: a comparative study of systemic therapy. Blood 125 (1): 71-81, 2015. [<ExternalRef xref="https://www.ncbi.nlm.nih.gov/pubmed/25336628">PUBMED Abstract</ExternalRef>]<Para id="_345">Cited in:</Para><ItemizedList id="_337" Style="bullet"><ListItem><SummaryRef href="CDR0000062881#_54" url="/types/lymphoma/hp/mycosis-fungoides-treatment-pdq">Treatment of Stage I and Stage II Mycosis Fungoides</SummaryRef></ListItem><ListItem><SummaryRef href="CDR0000062881#_73" url="/types/lymphoma/hp/mycosis-fungoides-treatment-pdq">Treatment of Stage III and Stage IV Mycosis Fungoides and Sézary Syndrome</SummaryRef></ListItem><ListItem><SummaryRef href="CDR0000062881#_102" url="/types/lymphoma/hp/mycosis-fungoides-treatment-pdq">Treatment of Recurrent Mycosis Fungoides and Sézary Syndrome</SummaryRef></ListItem></ItemizedList></ListItem><ListItem>Kadin ME, Hughey LC, Wood GS: Large-cell transformation of mycosis fungoides-differential diagnosis with implications for clinical management: a consensus statement of the US Cutaneous Lymphoma Consortium. J Am Acad Dermatol 70 (2): 374-6, 2014. [<ExternalRef xref="https://www.ncbi.nlm.nih.gov/pubmed/24438952">PUBMED Abstract</ExternalRef>]<Para id="_346">Cited in:</Para><ItemizedList id="_335" Style="bullet"><ListItem><SummaryRef href="CDR0000062881#_1" url="/types/lymphoma/hp/mycosis-fungoides-treatment-pdq">General Information About Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas</SummaryRef></ListItem></ItemizedList></ListItem><ListItem>	Quaglino P, Pimpinelli N, Berti E, et al.: Time course, clinical pathways, and long-term hazards risk trends of disease progression in patients with classic mycosis fungoides: a multicenter, retrospective follow-up study from the Italian Group of Cutaneous Lymphomas. Cancer 118 (23): 5830-9, 2012. [<ExternalRef xref="https://www.ncbi.nlm.nih.gov/pubmed/?term=22674564">PUBMED Abstract</ExternalRef>]<Para id="_331">Cited in:</Para><ItemizedList id="_332" Style="bullet"><ListItem><SummaryRef href="CDR0000062881#_1" url="/types/lymphoma/hp/mycosis-fungoides-treatment-pdq">General Information About Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas</SummaryRef></ListItem></ItemizedList></ListItem><ListItem>Talpur R, Singh L, Daulat S, et al.: Long-term outcomes of 1,263 patients with mycosis fungoides and Sézary syndrome from 1982 to 2009. Clin Cancer Res 18 (18): 5051-60, 2012. [<ExternalRef xref="https://www.ncbi.nlm.nih.gov/pubmed/?term=22850569">PUBMED Abstract</ExternalRef>]<Para id="_340">Cited in:</Para><ItemizedList id="_341" Style="bullet"><ListItem><SummaryRef href="CDR0000062881#_1" url="/types/lymphoma/hp/mycosis-fungoides-treatment-pdq">General Information About Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas</SummaryRef></ListItem></ItemizedList></ListItem></ItemizedList></SummarySection><SummarySection id="_212"><SectMetaData><SectionType>Changes to summary</SectionType></SectMetaData><Title>Latest Updates to This Summary (02/19/2025)</Title><Para id="_213">The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available.  This section describes the latest changes made to this summary as of the date above.</Para><Para id="_737"><Strong><SummaryRef href="CDR0000062881#_7" url="/types/lymphoma/hp/mycosis-fungoides-treatment-pdq">Cellular Classification of Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas</SummaryRef></Strong></Para><Para id="_738">Added <SummaryRef href="CDR0000062881#_736" url="/types/lymphoma/hp/mycosis-fungoides-treatment-pdq">text</SummaryRef> to state that established criteria for defining Sézary syndrome generally require identification of (1) a circulating T-cell clone by rearrangement of the T-cell receptor, plus (2) a level of Sézary cells in the blood of at least 1,000/μL (cited 2007 Olsen et al. as reference 3 and 2022 Olsen et al. as reference 4). It is less clear if other findings are reliable staging data in the absence of blood Sézary cell levels of at least 1,000/μL (cited Chrisman et al. as reference 5).</Para><Para id="_disclaimerHP_3">This summary is written and maintained by the <ExternalRef xref="https://www.cancer.gov/publications/pdq/editorial-boards/adult-treatment">PDQ Adult Treatment Editorial Board</ExternalRef>, which is
editorially independent of NCI.  The summary reflects an independent review of
the literature and does not represent a policy statement of NCI or NIH.  More
information about summary policies and the role of the PDQ Editorial Boards  in
maintaining the PDQ summaries can be found on the <SummaryRef href="CDR0000062881#_AboutThis_1" url="/types/lymphoma/hp/mycosis-fungoides-treatment-pdq">About This PDQ Summary</SummaryRef> and <ExternalRef xref="https://www.cancer.gov/publications/pdq">PDQ® Cancer Information for Health Professionals</ExternalRef> pages.
</Para></SummarySection><SummarySection id="_AboutThis_1"><Title>About This PDQ Summary</Title><SummarySection id="_AboutThis_2"><Title>Purpose of This Summary</Title><Para id="_AboutThis_3">This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of mycosis fungoides and other cutaneous T-cell lymphomas. It is intended as a resource to inform and assist clinicians in the care of their patients.  It does not provide formal guidelines or recommendations for making health care decisions.</Para></SummarySection><SummarySection id="_AboutThis_4"><Title>Reviewers and Updates</Title><Para id="_AboutThis_5">This summary is reviewed regularly and updated as necessary by the <ExternalRef xref="https://www.cancer.gov/publications/pdq/editorial-boards/adult-treatment">PDQ Adult Treatment Editorial Board</ExternalRef>, which is editorially independent of the National Cancer Institute (NCI).  The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).</Para><Para id="_AboutThis_22"> Board members review recently published articles each month to determine whether an article should:</Para><ItemizedList id="_AboutThis_6" Style="bullet"><ListItem>be discussed at a meeting,</ListItem><ListItem>be cited with text, or</ListItem><ListItem>replace or update an existing article that is already cited.</ListItem></ItemizedList><Para id="_AboutThis_7">Changes to the summaries are made through a consensus process in which Board members evaluate the strength of the evidence in  the published articles and determine how the article should be included in the summary.</Para><Para>The lead reviewers for Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas Treatment are:</Para><ItemizedList Style="bullet"><ListItem>Eric J. Seifter, MD (Johns Hopkins University)</ListItem><ListItem>Cole H. Sterling, MD (Johns Hopkins University)</ListItem></ItemizedList><Para id="_AboutThis_9">Any comments or questions about the summary content should be submitted to Cancer.gov through the NCI website's <ExternalRef xref="https://www.cancer.gov/contact/email-us">Email Us</ExternalRef>. Do not contact the individual Board Members with questions or comments about the summaries. Board members will not respond to individual inquiries.</Para></SummarySection><SummarySection id="_AboutThis_10"><Title>Levels of Evidence</Title><Para id="_AboutThis_11">Some of the reference citations in this summary are accompanied by a level-of-evidence designation. These designations are intended to help readers assess the strength of the evidence supporting the use of specific interventions or approaches. The PDQ Adult Treatment Editorial Board uses a <SummaryRef href="CDR0000062796" url="/publications/pdq/levels-evidence/treatment">formal evidence ranking system</SummaryRef> in developing its level-of-evidence designations.</Para></SummarySection><SummarySection id="_AboutThis_12"><Title>Permission to Use This Summary</Title><Para id="_AboutThis_13">PDQ is a registered trademark. Although the content of PDQ documents can be used freely as text, it cannot be identified as an NCI PDQ cancer information summary unless it is presented in its entirety and is regularly updated. However, an author would be permitted to write a sentence such as “NCI’s PDQ cancer information summary about breast cancer prevention states the risks succinctly: [include excerpt from the summary].”</Para><Para id="_AboutThis_14">The preferred citation for this PDQ summary is:</Para><Para id="_AboutThis_15">PDQ® Adult Treatment Editorial Board. PDQ Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas Treatment. Bethesda, MD: National Cancer Institute. Updated  &lt;MM/DD/YYYY&gt;. Available at: <ExternalRef xref="https://www.cancer.gov/types/lymphoma/hp/mycosis-fungoides-treatment-pdq">https://www.cancer.gov/types/lymphoma/hp/mycosis-fungoides-treatment-pdq</ExternalRef>.  Accessed &lt;MM/DD/YYYY&gt;. [PMID: 26389288]</Para><Para id="_AboutThis_16">Images in this summary are used with permission of the author(s), artist, and/or publisher for use within the PDQ summaries only. Permission to use images outside the context of PDQ information must be obtained from the owner(s) and cannot be granted by  the National Cancer Institute. Information about using the illustrations in this summary, along with many other cancer-related images, is available in <ExternalRef xref="https://visualsonline.cancer.gov/">Visuals Online</ExternalRef>, a collection of over 2,000 scientific images.

</Para></SummarySection><SummarySection id="_AboutThis_17"><Title>Disclaimer</Title><Para id="_AboutThis_18">Based on the strength of the available evidence, treatment options may be described as either “standard” or “under clinical evaluation.” These classifications should not be used as a basis for insurance reimbursement determinations. More information on insurance coverage is available on Cancer.gov on the <ExternalRef xref="https://www.cancer.gov/about-cancer/managing-care">Managing Cancer Care</ExternalRef> page.</Para></SummarySection><SummarySection id="_AboutThis_20"><Title>Contact Us</Title><Para id="_AboutThis_21">More information about contacting us or receiving help with the Cancer.gov website can be found on our <ExternalRef xref="https://www.cancer.gov/contact">Contact Us for Help</ExternalRef> page. Questions can also be submitted to Cancer.gov through the website’s <ExternalRef xref="https://www.cancer.gov/contact/email-us">Email Us</ExternalRef>.</Para></SummarySection></SummarySection><DateLastModified>2025-02-19</DateLastModified></Summary>
